   
 
12G.616 Protocol v4.2 (04Jan2016)  1 
THOMAS JEFFERSON UNIVERSITY 
Kimmel Cancer Center 
 
CAREFOR Study: A Feasibility Pi[INVESTIGATOR_853716]:  Nicole Simone, MD  
 
 
[PHONE_11122]  
Co-Investigator(s):   
 
 
 
 
 
 
 
 
 
  
  
 
Non-consenting  
Co-Investigator(s):   
 
 
Funding Sponsor:  Ladies of Port Richmond Pi[INVESTIGATOR_853717]:  Date:  
Initial , 1  11/7/12  
AMDT. 2  4/3/13  
3.0 12/3/2013  
4.0 5/21/2014  
4.1 1/9/2015  
4.2 1/4/2016  
 
CONFIDENTIAL 
This document is confidential and the property of THOMAS JEFFERSON UNIVERSITY.  No part of it may 
be transmitted, reproduced, published, or used by [CONTACT_853747]. 
  

   
 
12G.616 Protocol v4.2 (04Jan2016)  2 
Table of Contents 
1 INTRODUCTION .............................................................................................................................................. 9 
 Specific Aims and Hypothesis .................................................................................................................... 9 1.1
 Background and Rationale .......................................................................................................................... 9 1.2
 Study Therapy .......................................................................................................................................... 11 1.3
 Preclinical Data ........................................................................................................................................ 11 1. 4
 Clinical Data to Date ................................................................................................................................ 14 1.5
 Dose Rationale and Risk/Benefits ............................................................................................................ [ADDRESS_1188327] SELECTION AND WITHDRAWAL .......................................................................................... 19 
 Inclusion Criteria ...................................................................................................................................... 19 4.1
 Exclusion Criteria ..................................................................................................................................... 20 4. 2
 Gender/Minority/Pediatric Inclusion for Research ................................................................................... [ADDRESS_1188328] Recruitment and Screening .......................................................................................................... 21 4.4
 Early Withdrawal of Subjects ................................................................................................................... 22 4.5
 When and How to Withdraw Subjects ............................................................................................... 22 4.5.1
 Data Collection and Follow-up for Withdrawn Subjects .................................................................. 22 4.5.2
5 STUDY DRUG/THERAPY ............................................................................................................................. 23 
 Descrip
tion ............................................................................................................................................... 23 5.1
 Treatment Regimen .................................................................................................................................. 23 5. 2
 Prior to lumpectomy: ........................................................................... Error! Bookmark not defined.  5.2.1
 Prior to Radiation: ............................................................................................................................ 23 5.2.2
 Risks of Caloric Restriction ...................................................................................................................... 23 5.3
 Method for Assigning Subjects to Treatment Groups .............................................................................. 24 5. 4
 Preparation and Administration of Study Drug/Therapy .......................................................................... 24 5.5
 Compliance Monitoring ............................................................................................................................ 24 5.6
 Prior and Concomitant Therapy ................................................................................................................ 25 5.7
6 STUDY PROCEDURES .................................................................................................................................. 25 
 Tr
eatment Overview ................................................................................................................................. 25 6.1
 Study Visit Schedule ................................................................................................................................ 25 6.2
 Screening ........................................................................................................................................... 25 6.2.1
 Phase Iâ€”Pre-treatment ..................................................................................................................... 25 6.2.2
 Phase IIâ€”Visits During Radiation Treatment ................................................................................... 26 6. 2.3
 Phase IIIâ€”Post Radiation Treatment ................................................................................................ 26 6.2.4
 Study Flowchart ........................................................................................................................................ 27 6. 3
 Radiation Treatment ................................................................................................................................. 28 6.4
 Dose Specifications ........................................................................................................................... 28 6.4.1
 Technical Factors .............................................................................................................................. 28 6.4.2
 Localization, Simulation, and Immobilization ................................................................................... 29 6. 4.3
 Treatment Planning/Target Volumes ................................................................................................. 29 6.4.4
 Treatment Verification ............................................................................................................................. 30 6. 5
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188329] treatment: ....................................................................................................................... 30 6.5.1
 Subsequent images or films: .............................................................................................................. [ADDRESS_1188330] Population(s) for Analysis ........................................................................................................... [ADDRESS_1188331]-study Adverse Event .................................................................................................................. 32 8.1.6
 Abnormal Laboratory Values ............................................................................................................ 33 8.1.7
 Hospi[INVESTIGATOR_059], Prolonged Hospi[INVESTIGATOR_146706] .................................................................... 33 8.1.8
 Recording of Adverse Events ................................................................................................................... 33 8.2
 Unblinding Procedures ............................................................................................................................. 34 8. 3
 Stoppi[INVESTIGATOR_1869] .......................................................................................................................................... 34 8.4
 Data and Safety Monitoring Plan ............................................................................................................. 34 8.5
 Medical Monitoring and AE/SAE Reporting ..................................................................................... [ADDRESS_1188332] .................................................................................................................................... 39 12.2
13 PUBLICATION PLAN .................................................................................................................................... 39 
14 SPECIMEN BANKING ................................................................................................................................... 39 
15 REFERENCES ................................................................................................................................................. 39 
16 APPENDICES .................................................................................................................................................. 41 
 
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188333] of Abbreviations 
 
BrCa: breast cancer 
CR: caloric restriction 
RT: radiation 
IGF: insulin-like growth factor  
NCI: National Cancer Institute 
BCT: Breast conserving therapy 
TJUH: Thomas Jefferson University Hospi[INVESTIGATOR_307] 
 
 
 
 
 
 
 
   
 
12G.616 Protocol v4.2 (04Jan2016)  5 
Study Summary 
Title CAREFOR study: A feasibility pi[INVESTIGATOR_853718]: Caloric Restriction for Oncology Research  
Phase  Pi[INVESTIGATOR_853719]/  
Study Design  Single site (early stage breast cancer), Pi[INVESTIGATOR_853720]  5 years  
Study Center(s)  Thomas Jefferson University Hospi[INVESTIGATOR_307]  
   
 
12G.616 Protocol v4.2 (04Jan2016)  6 
Objectives  The primary objectives are as follows:  
The study will be condu cted in two phases. The first phase will enroll 
40 patients. At the end of it, we will determine adherence to CR. We 
will then proceed to the second phase which will enroll an additional 
50 patients, for a total study sample size of 90 , and at its end we w ill 
assess toxicity, as well as potential predictors of it . 
Phase 1:  Investigate the feasibility of a clinical trial administering ionizing 
radiation with concurrent CR for the treatment of breast cancer. True 
adherence will be defined as a successful redu ction of 25% of total calories 
based on diet journals in at least 80% of the logged events.  
Phase 2: Acute skin toxicity as defined by [CONTACT_853748] (NCI CTCv.[ADDRESS_1188334] de squamation ) will be followed to ensure 
noninferiority as compared with historical controls.  
The secondary objectives are as follows:  
Investigate measurable changes of patient characteristics and tissue and 
serum from fasting/CR  conditions to determine a me tric for evaluating this 
treatment in future studies.  
ï‚· Weight:  Weight will be monitored by [CONTACT_43658], at baseline, week 
1, 3, 5 and 7, conclusion and 4 weeks after diet is complete.  Body fat 
measurements via calipers and bioimpedance which will be don e at 
baseline, conclusion and 4 weeks after diet is completed.   Vital signs will 
be monitored weekly.  
ï‚· Serum:   
ï‚· At initiation of diet, conclusion of diet and 4 weeks after diet is 
complete, fasting labs will be drawn:  
ï‚· Clinical Lab: CBC, basic metabolic panel , hemoglobin A1C, 
triglycerides, insulin, IGF -1, erythrocyte sedimentation rate (ESR), 
adiponectin, leptin and estradiol  
ï‚· Other Serum Markers:   IGF-1R, IRS -1, proteomic  and/or genomic 
analysis  
ï‚· At week 5: a fasting insulin level will be evaluated.  
ï‚· Psycho -social evaluation : Patients will have psycho -social evaluation 
using the  FACT -B test and the PROMIS cancer fatigue short form at 
baseline, week 5, conclusion and 4 weeks after conclusion.  
ï‚· Outcomes:  Local recurrence, progression free survival, distant 
metastas es and overall survival will be assessed through patient records 
after study has been completed.  
ï‚· Toxicity:  acute skin reaction or pain using the National Cancer Institute 
Common Toxicity Criteria (NCI CTC) version 4.[ADDRESS_1188335] also been treated for a 6  â€“ 6.5 
week course of radiation.   
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188336]  
 
Study Therapy, 
Dose, Route, 
Regimen  Radiation and Caloric Restriction: a 25% reduction in total caloric intake  
Duration of 
administration 
and follow -up Caloric Restriction for 10weeks (2weeks minimum prior to radiation, during [ADDRESS_1188337] 
10weeks) with a follow up visit 4 weeks after treatment completion.  
Reference 
therapy  Patients acute toxicity on this trial will be compared with historic controls of 
other patients who received 6 -6.5 weeks of radiation at Bodine Cancer Center  
Statistical 
Methodology  The study w ill enroll a total of 90 patients. Phase 1: With a sample size  of 40 , 
the study has 83% power to establish that adherence is higher than 60%,  
assuming that true adherence will be 80% or greater (one -sided 
exact  binomial test with alpha 0.05).  Phase 2: We w ill compute the proportion 
of patients with toxicity, along with a 95% exact confidence interval. Our 
institutionâ€™s historical toxicity rate among similar patients is about 80% and we 
aim to prove that the dietary intervention is non -inferior with an absol ute 
margin of 10%, using an exact binomial test. With a total sample size of 90 
and assuming that true toxicity will be 80% or lower, we have 82% power 
(with one -sided alpha of 0.05).  
   
 
12G.616 Protocol v4.2 (04Jan2016)  8 
Schema  
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  9 
 INTRODUCTION 1
This document is a protocol for a human research study. This study is to be conducted 
according to US and international standards of Good Clinical Practice (FDA Title 21 part 
312 and International Conference on Harmonization guidelines), applicable government 
regulations and Institutional research policies and procedures.  
 Specific Aims and Hypothesis 1.1
We hypothesize that a dietary change such as fasting may alter tumor biology. Further 
we hypothesize that a 25% reduction in caloric intake is a feasible intervention for 
early stage breast cancer patients to adhere to during radiation therapy. 
To this end, in this feasibility trial we will (1) investigate the feasibility of a clinical trial 
administering ionizing radiation with concurrent CR for the treatment of breast cancer 
(2) Acute skin toxicity as defined by [CONTACT_684244] (NCI CTCv.[ADDRESS_1188338] 
desquamation) will be followed to ensure noninferiority as compared with historical 
controls. (3) investigate measurable changes of patient characteristics along with 
serum markers from CR to determine a metric for evaluating this treatment in future 
studies.  
The use of caloric restriction as a novel intervention has the potential to change the 
biology of tumors and enhance the clinical benefit of standard cancer therapi[INVESTIGATOR_014]. If this 
trial is successful and it is determined that patients can achieve successful caloric 
restriction during breast cancer treatment, the long term goal will be to open a larger 
study to determine if this treatment is more efficacious than using radiation alone. 
 Background and Rationale 1.2
CR, or a diet modification aiming to reduce the total intake of calories by 20-30%, has 
been shown to increase longevity across multiple species.  Recently, there has been 
growing interest in the potential role of CR as a treatment modality for age-related 
diseases such as cancer because an increasing body of literature has demonstrated 
that there is a metabolic component to both carcinogenesis and tumor progression. In 
fact, many of the molecular pathways that are induced by [CONTACT_240316], such as IGF1-R, Akt 
and mTOR pathways, are also known to be perturbed in cancer and are currently 
targ
ets of novel cancer therapi[INVESTIGATOR_014]. Therefore, alteration of multiple steps in these 
pathways by [CONTACT_853749]. 
CR has been shown to decrease the incidence and progression of spontaneous 
breast cancers in murine models, and to protect normal tissue during chemotherapy.  
Our preliminary results show that CR represses tumor growth in an additive manner 
when combined with radiation in 2 different aggressive murine models (4T1 and 
67NR) of breast cancer (Fig 1).  Our results at the molecular level demonstrate that 
various components of the IGF-1R pathway are downregulated with CR and RT used 
separately, and are further decreased by [CONTACT_853750], suggesting a 
role for CR in the observed repression of tumor growth (Fig 2).    
   
 
12G.616 Protocol v4.2 (04Jan2016)  10 
Figure 1: Tumor re-growth-delay curves for tumors created from 4T1 breast cancer cell 
line: Ten mice were treated with either: ad libitum (AL) diet, radiation (RT), a 30% reduction in 
their calories (CR), or CR + RT. Compared to the AL cohort, for 4T1 tumors at 1000mm3 RT 
produced a 23% growth delay, CR 56%, and CR+RT 82%.  
 
 
Figure 2. Expression of members of the IGF-1R pathway.  RT-PCR was performed for 
molecules in the IGF-1R pathway(IGF-1R, IRS, PIk3ca, and mTOR).  For all of these 
molecules, CR, radiation, and the combination of both treatments resulted in downregulation 
which implicates this pathway in mediating the tumor regression noted.   
 
Although the preclinical data appears promising, it is unknown if patients will want to 
or be able to adhere to a reduction in calories during radiation therapy.  In the 
radiation clinic, many patients inquire about potentially beneficial dietary alterations. 
Although CR requires a significant commitment, we have shown through a TJUH IRB 
approved questionnaire that 75% of breast cancer patients queried at our institution 
would be interested in enrolling on such a diet related intervention trial (manuscript 
under review).  Because CR may act as a complementary therapeutic modality in the 
treatment of women with breast cancer, its full capacity as a therapeutic intervention 
needs to be assessed.   
It seems logical to propose that combining CR with genotoxic therapi[INVESTIGATOR_853721], in the treatment of breast cancer, could both retard tumor progression as 
well as confer significant therapeutic advantage by [CONTACT_853751] 

   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188339] 
beneficial for women to use in a larger randomized trial based on the results obtained 
here.  
Specific Aim 1: In a clinical trial, will investigate the ability of CR to modulate 
the effects of radiation in the treatment of early breast cancer. Aim 1a. Adherence 
will be assessed and is defined for each patient as achieving 25% reduction of her 
normal caloric intake (weekly average of diet journals), during at least 80% of the days 
during the intervention. Aim 1b. Acute skin toxicity as defined by [CONTACT_853748] (NCI CTCv.[ADDRESS_1188340] desquamation) will be followed to ensure noninferiority as 
compared with historical controls. Specific Aim 2: Investigate measurable changes 
of patient characteristics along with serum markers fr om CR to determine a 
metric for evaluating this treatment in future studies.  Patient characteristics such 
as weight, vital signs, body fat measurements, psychosocial evaluation and outcomes 
will be monitored. Additionally, members of the IGF- 1R-AKT pathway, and glucose 
and insulin in the serum, will be assessed to create a molecular signature [CONTACT_853767].   
The innovative use of caloric restriction as a novel therapeutic option has the potential 
to change the biology of tumors and enhance the clinical benefit of current treatments 
for breast cancer. If patients are noted to be compliant, we will be able to open a 
larger study to determine if the combination of radiation and caloric restriction is more 
efficacious than radiation alone. 
 Study Therapy 1.3
Baseline caloric intake will be assessed by [CONTACT_853752] 7-10 days prior to radiation 
treatment planning. Recommendations by [CONTACT_853753] 25% and the patient will begin this diet immediately 
after the planning session and for [ADDRESS_1188341] generated a reproducible mouse model to 
assess various modalities of treatment. Specifically, we tested the syngeneic and 


*3URWRFROY-DQ  
KLJKO\PHWDVWDWLF7FHOOOLQHVLQ RXUPRGHO)HPDOH%DOEFP LFHDWSRVWQDWDOZHHN
ZHUHLPSODQWHGZLWK[ 7WXPRUFHOOVLQWRWKHPD[COMPANY_003]U \IDWSDGDQG
WXPRUVZHUHPHDVXUHG WLPHVSHUZHHNXVLQJPDQXDOFDOLSHUV0 LFHZHUH
HXWKDQL]HGZKHQWXPRUVUHDFKHGFP
)LJXUH7ULDO'HVLJQ 7KHIRRGLQWDNHRIPLFHPRQLWR UHGIRUZHHNVEHIRUHWXPRUV
ZHUHLPSODQWHGLQWRWKHPD[COMPANY_003]U\IDWSDGRIPLFH

,QWHUYHQWLRQ &RKRUWVFRQVLVWLQJRIPLFHHDFK ZHUHWUHDWHGDVVKRZQ)LJ ZLWK
HLWKHUUDGLDWLRQGLHWDU\LQWHUY HQWLRQDORQHRULQFRPELQDWLRQ ZLWKUDGLDWLRQDIWHUWKH
WXPRUVZHUHSDOSDEOHWRDQDYHUDJ HVL]HRIPP7KHGLHWVZ HUHHLWKHUDGOLELWXP
$/IHHGLQJRUDUHGXFWLRQLQ FDORULFLQWDNHRYHUDQG D\SHULRGDQLPDOVZHUH
VWHSSHGGRZQLQLQFUHPHQWV WRHQVXUHDQLPDOWROHUDELOLW\ $YHUDJHIRRGLQWDNH
SHUDQLPDOZDVGHWHUPLQHGIRUDOOJ URXSVE\ZHLJKLQJIRRGW LPHVZHHNDIWHUWKH
DQLPDOVZHUHVLQJO\KRXVHGIRUDWO HDVWWZRZHHNVSULRUWRLPSO DQWDWLRQ:KHQWKH
WXPRUEHFDPHSDOSDEOHaPPD SSUR[LPDWHO\ZHHNDIWHULPSO DQWDQLPDOV
UHFHLYHGHLWKHUDGLHWPRGLILFDWLRQZHUHUDGLDWHGWRWKHSULPD U\WXPRURUUHFHLYHG
ERWKWUHDWPHQWV7RHVWDEOLVKWKHGRVHRIUDGLDWLRQWRWUHDWP LFHLPSODQWHGZLWK7
FHOOVFORQRJHQLFDVVD\VZHUHSH UIRUPHGDQGDGRVHRIUDGLDWLRQ ZDVFKRVHQWR
DFKLHYHDFHOONLOOLQYLWUR $IWHUWKHDQLPDOVKDGSDOSDE OHWXPRUVWKH\ZHUH
SODFHGLQDFXVWRPMLJDQGDGR VHRI*\ZDVDGPLQLVWHUHGWRW KHSULPDU\WXPRUVZLWK
WKHUHVWRIWKHLUERGLHVVKLHOGHG 3ULPDU\WXPRUYROXPHZDVPHD VXUHGWLPHVSHU
ZHHNDQGLVUHSUHVHQWHGLQ)LJ
ZHHN
3DOSDEOHWXPRU
aPP$OORZWXPRUJURZWK
WRaPP
1R7UHDWPHQW 5DGLDWLRQ &KHPRWKHUDS\
$G/LELWXP $G/LELWXP $G/LELWXP
$') $') $')
&5GLHW &5GLHW &5GLHW2UWKRWRSLFWXPRULQMHFWLRQ
[FHOOV
5DQGRPL]HWR
DUDGLDWLRQGLHW
DUPWXPRUVZHUHLPSODQWHGLQWRWKHPD[COMPANY_003]U\IDWSDGRIPLFH
   
 
12G.616 Protocol v4.2 (04Jan2016)  13 
Figure 4: Tumor re-growth-delay curves for tumors created from 4T1 breast 
cancer cell line. Ten mice were treated with either: ad libitum (AL) diet, radiation 
(RT), a 30% reduction in their calories (CR), or CR + RT. Compared to the AL cohort, 
for 4T1 tumors at 1000mm3 RT produced a 23% growth delay, CR 56%, and CR+RT 
82%.  
 
CR alters the IGF-1R survival-signaling pathway 
To determine if altering the IGF-1R pro-survival pathway might be responsible for the 
additive tumor regression noted between CR and irradiation, q RT-PCR was performed 
on grossly dissected 4T1 tumors from the previous experiment using primers for IGF-
1R, IRS, PIk3ca, and mTOR. 
Figure 5: Expression of members of the IGF-1R pathway.   RT-PCR was performed 
for molecules in the IGF-1R pathway(IGF-1R, IRS, PIk3ca, and mTOR).  For all of 
these molecules, CR, radiation, and the combination of both treatments resulted in 
downregulation which implicates this pathway in mediating the tumor regression 
noted.   
 
These results (Fig. 5) demonstrated that multiple molecules in the IGF-1R/AKT 
pathway are downregulated with CR alone or in combination with radiation.  Since the 

   
 
12G.616 Protocol v4.2 (04Jan2016)  14 
IGF-1R/AKT is involved in apoptosis and based on these results we propose that this 
work warrants further investigation of this pathway is warranted in order to determine 
whether pathway components contribute to the beneficial effects of CR in breast 
cancer. 
 Clinical Data to Date 1.[ADDRESS_1188342] been no published trials assessing radiation therapy with a diet 
modification to date, there are now a number of registered trials 
(www.clinicaltrials.gov ) assessing a ketogenic diet with cancer therapy for lung 
cancer, pancreatic cancer, primary brain tumors and metastatic cancer. 
There are published trials in the non-oncologic realm however; showing that caloric 
restriction is feasible and patients are able to be compliant in other diseases or in 
healthy volunteers. For example, the Comprehensive Assessment of Long-term 
Effects of Reducing Intake of Energy (CALERIE) is a multi-center randomized 
controlled trial that placed patients on a 25% caloric reduction for [ADDRESS_1188343] in Arizona, where patients were 
kept on a CR diet of1,780 kcal/day for [ADDRESS_1188344] in a CR Clinical Trial: Many patients express an interest in dietary 
changes they can make to improve their cancer survival but the data supporting such 
interventions is scarce.  To begin to develop a protocol for using CR to treat patients, 
we set out to assess the feasibility of using CR in a clinical setting. Specifically, we 
distributed an IRB-approved questionnaire to our oncology patients querying patient 
interest in participating in a CR study. We found that 75% would participate in a CR 
trial. The patients identified several tools they believed would help them with dietary 
trial adherence including speaking with a dietician weekly and weekly phone 
conversations with the physician.  This demonstrates that there is patient interest in 
dietary interventions and that a trial using CR could successfully accrue patients. We 
have since worked with the Integrative Medicine Department to develop a strategy to 
implement a CR diet and to monitor and ensure adherence.  
 Dose Rationale and Risk/Benefits 1.6
The patients will undergo a 25% reduction in total caloric intake since this is a) the 
reduction used in other clinical trials that employ caloric restriction and, b) the 
definition of caloric restriction and the percent reduction noted to effect molecular 
targets in the IGF pathway. 
The patients will undergo CR for a total of [ADDRESS_1188345] 5 weeks for stabilization of physiologic processes 
   
 
12G.616 Protocol v4.2 (04Jan2016)  15 
under caloric restriction [1].  
The diet modification proposed should not induce many risks, and every effort will be 
made to insure that patients are receiving adequate overall nutrition.  Although some 
patients may experience weight loss and fatigue, other risks should be minimal. These 
risks may include: decreased bone mineral density, decreased muscle mass and 
strength, depression, decreased sex drive, fatigue, irritability, fainting, rashes, 
acidosis, malnutrition, constipation, dehydration, cholelithiasis and reversible 
amenorrhea.  
Because obesity has been proven a poor prognostic factor in those patients with 
breast cancer, dietary intervention may be ideal for improving outcomes for these 
patients who decrease their caloric intake. 
 STUDY OBJECTIV ES [ADDRESS_1188346] cancer. True adherence will be defined as a 
successful reduction of 25% of total calories based on diet journals in at least 80% of 
the logged events. 
Aim 1b. Acute skin toxicity as defined by [CONTACT_853754] (NCI CTCv.[ADDRESS_1188347] 
desquamation) will be followed to ensure noninferiority as compared with historical 
controls. 
 Secondary Objective  2.2
Investigate measurable changes of patient characteristics and tissue and serum from 
fasting/CR conditions to determine a metric for evaluating this treatment in future 
studies. 
ï‚· Weight: Weight will be monitored by [CONTACT_43658], at baseline, week 1, 3, 5 and 7, 
conclusion and 4 weeks after diet is complete. Body fat measurements via calipers and 
bioimpedance which will be done at baseline, conclusion and 4 weeks after diet is 
completed. Vital signs will be monitored weekly. 
ï‚· Serum: 
ï‚· At initiation of diet, conclusion of diet and 4 weeks after diet is complete, fasting 
labs will be drawn:  
ï‚· Clinical Lab: CBC, basic metabolic panel, hemoglobin A1C, triglycerides, 
insulin, IGF-1, erythrocyte sedimentation rate (ESR), adiponectin, leptin 
and estradiol 
ï‚· Other Serum Markers:   IGF-1R, IRS-1, genomic and or proteomic 
analysis 
ï‚· At week 5: a fasting insulin level will be evaluated. 
   
 
12G.616 Protocol v4.2 (04Jan2016)  16 
ï‚· Psycho-social evaluation:   Patients will have psycho-social evaluation using the FACT-
B test and the PROMIS cancer fatigue short form at baseline, week 5, conclusion and 4 
weeks after conclusion. 
ï‚· Outcomes: Local recurrence, progression free survival, distant metastases and overall 
survival will be assessed through patient records after study has been completed. 
ï‚· Toxicity: acute skin reaction or pain using the National Cancer Institute Common Toxicity 
Criteria (NCI CTC) version 4.[ADDRESS_1188348] also been treated for a 6 week 
course of radiation.  
 Study Design 3
 General Design 3.1
ï‚· This is a pi[INVESTIGATOR_853722]. 
ï‚· Expected duration of subject participation: approximately 20 weeks, with 10 weeks of diet and 
follow up 
ï‚· Section 6.1 outlines the specific trial periods. 
   
 
12G.616 Protocol v4.2 (04Jan2016)  17 
 
 Primary Study Endpoints 3.2
Objective:  Investigate the feasibility of a clinical trial administering ionizing radiation 
with concurrent CR for the treatment of breast cancer. True adherence will be defined 
as a successful reduction of 25% of total calories based on diet journals in at least 
80% of the logged events. Acute skin toxicity as defined by [CONTACT_853748] (NCI CTCv.[ADDRESS_1188349] desquamation) will be followed to ensure noninferiority as 
compared with historical controls. 
To obtain baseline caloric intake, patients will keep food diaries for 7 to 10 days. On 
the basis of these diaries, a caloric intake will be computed for each day. Each 
patient's baseline (pre-diet) caloric intake will then be the average caloric intake in this 
pre-diet phase. The target caloric intake during the diet phase will be set to 75% of 
this baseline average (25% restriction). 

   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188350] 80% of all logged events meeting the diet restriction target. 
 Secondary Study Endpoints 3.3
Investigate measurable changes of patient characteristics and tissue and serum from 
fasting/CR conditions to determine a metric for evaluating this treatment in future 
studies. 
ï‚· Weight: Weight will be monitored as a percent change and by [CONTACT_853755], at baseline, week 1, 3, 5 and 7, 
conclusion and 4 weeks after diet is complete.  
ï‚· Body Fat Measurement: Body fat percentage will be done at baseline, conclusion and [ADDRESS_1188351] and base of fold. A 
pi[INVESTIGATOR_853723] 1 to 2 seconds before reading the 
caliper. Duplicate measurements will be taken at each site, allowing time for skin to 
regain normal texture and thickness. Measurements will be taken at the: 
ï‚· Biceps: Measured on a vertical fold at the upper arms frontside, half way between 
shoulder and elbow. 
ï‚· Triceps: Measured on a vertical fold at mid of the upper arms backside. 
ï‚· Scapula: Measured on a diagonal fold on the back, at the lower edge of the scapula. 
Angle of inclination should be 45Â°, clockwise. 
ï‚· Hip: Measured on a diagonal fold straight over the pelvis, close to the navel. Angle of 
inclination should be 30Â°, clockwise. 
ï‚· Bioimpedance: Bioimpedance will be taken at baseline, conclusion and 4 weeks after 
diet is completed and will be measured in Î©/m2. 
ï‚· Vitals: Vital signs including temperature, blood pressure, heart rate and respi[INVESTIGATOR_853724]. 
ï‚· Serum (collection procedures detailed in Appendix VI ): 
ï‚· At initiation of diet, conclusion of diet and 4 weeks after diet is complete, fasting labs 
will be drawn: 
ï‚· Clinical Lab: CBC, basic metabolic panel, hemoglobin A1C, triglycerides, insulin, 
IGF-1, erythrocyte sedimentation rate (ESR), adiponectin, leptin and estradiol 
ï‚· Other Serum Markers:   IGF-1R, IRS-1, genomic and/or proteomic analysis 
ï‚· At week 5: a fasting insulin level will be evaluated. 
   
 
12G.616 Protocol v4.2 (04Jan2016)  19 
ï‚· Psycho-social evaluation:   Patients will have psycho-social evaluation using the FACT-
B test and the PROMIS cancer fatigue short form at baseline, week 5, conclusion and 4 
weeks after conclusion. (Forms detailed in CRFs in Appendix VII) 
ï‚· Outcomes: Local recurrence, progression free survival, distant metastases and overall 
survival will be assessed through patient records after study has been completed. 
ï‚· Toxicity: acute skin reaction or pain using the National Cancer Institute Common Toxicity 
Criteria (NCI CTC) version 4.0 scale22 will be assessed. Number of patients 
experiencing toxicity and time to occurrence of toxicity will be recorded (see Appendix III 
for toxicity scale). This toxicity will be compared to historical controls from TJUH who 
have also been treated for a 6-6.5 week course of radiation.  
 Primary Safety Endpoints 3.4
Acute toxicities will be evaluated by [CONTACT_396511], Version 4.0. ( htt p://ctep.info.nih.gov ). 
If a patient has a serious adverse event such as all unexpected hospi[INVESTIGATOR_853725] [ADDRESS_1188352] be female 3.
 Age â‰¥ [ADDRESS_1188353] be able to be resected through a single 5.
lumpectomy incision  
 Appropriate stage for protocol entry, including no clinical evidence for distant 6.
metastases, based upon the following minimum diagnostic workup: 
ï‚· History/physical examination, including breast exam and documentation of 
weight and Karnofsky Performance Status of 80-100% at study entry.  
 Women of childbearing potential must be non-pregnant and non-lactating and willing t o 7.
use medically acceptable form of contraception during radiation therapy 
 Patient must capable of and provide study specific informed consent prior to study 8.
entry 
 BMI â‰¥21  9.
   
 
12G.616 Protocol v4.2 (04Jan2016)  20 
 Weight â‰¥100lbs   10.
 No prior history of non-breast invasive malignancies in the past [ADDRESS_1188354] any of the following severe, active co-morbidity, defined as 12.
follows: 
ï‚· Unstable angina and/or congestive heart failure requiring hospi[INVESTIGATOR_390381] 6 months 
ï‚· Transmural myocardial infarction within the last 6 months 
ï‚· Acute bacterial or fungal infection requiring intravenous antibiotics at the time of 
registration; 
ï‚· Chronic Obstructive Pulmonary Disease exacerbation or other respi[INVESTIGATOR_533032] 30 days before 
registration; 
ï‚· Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; 
note, however, that laboratory tests for liver function and coagulation parameters 
are not required for entry into this protocol 
ï‚· Acquired Immune Deficiency Syndrome (AIDS) or HIV positive based upon 
current CDC definition; note, however, that HIV testing is not required for entry 
into this protocol. The need to exclude patients with AIDS or HIV from this 
protocol is necessary because anti-retrivirals may alter patient metabolism. 
ï‚· Gastrointestinal/Malabsorption disorder at the discretion of the Principal 
Investigator 
ï‚· Inflammatory Bowel Disease 
ï‚· Celiac Disease 
ï‚· Chronic Pancreatitis 
ï‚· Chronic Diarrhea or Vomiting 
ï‚· Active Eating Disorder 
ï‚·  
 Patient must not have active systemic lupus erythematosus, or any history of active 13.
scleroderma, or dermatomyositis with active rash 
 No prior radiotherapy to the ipsilateral breast or prior radiation to the region of the 14.
breast that would result in overlap of radiation therapy fields 
 Not currently taking steroids 15.
 No history of or current active drug/alcohol dependence.   16.
 No patients being decisionally impaired. 17.
 Exclusion Criteria 4.[ADDRESS_1188355] conservation. 1.
 Patient is male. 2.
 Age <18 years 3.
 Patient requires regional lymph node irradiation therapy 4.
 Patient has evidence of distant metastases 5.
 Karnofsky Performance Status less than 80% within 60 days prior to study. 6.
 Ipsilateral mammogram done greater than 6 months prior to study. 7.
 Women of childbearing potential with a positive serum beta hCG. 8.
 Patient unable to consent or comply with study guidelines. 9.
 BMI < 21 10.
 Weight < 100lbs 11.
 Unintentional weight loss â‰¥10% in the last 3 mos 12.
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188356] 16.
that would result in overlap of radiation therapy fields 
 Severe, active co-morbidity, defined as follows: 17.
ï‚· Unstable angina and/or congestive heart failure requiring hospi[INVESTIGATOR_390381] 6 months 
ï‚· Transmural myocardial infarction within the last 6 months 
ï‚· Acute bacterial or fungal infection requiring intravenous antibiotics at the time of 
registration; 
ï‚· Chronic Obstructive Pulmonary Disease exacerbation or other respi[INVESTIGATOR_533032] 30 days before 
registration; 
ï‚· Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; 
note, however,that laboratory tests for liver function and coagulation parameters 
are not required for entry into this protocol 
ï‚· Acquired Immune Deficiency Syndrome (AIDS) or HIV positive based upon 
current CDC definition; note,however, that HIV testing is not required for entry 
into this protocol. The need to exclude patients with AIDS or HIV from this 
protocol is necessary because anti-retrivirals may alter patient metabolism. 
 Active systemic lupus erythematosus, or any history of active scleroderma, 18.
dermatomyositis with active rash 
 Active Gastrointestinal/Malabsorption disorder at the discretion of the Principal 19.
Investigator 
ï‚· Inflammatory Bowel Disease 
ï‚· Celiac Disease 
ï‚· Chronic Pancreatitis 
ï‚· Chronic Diarrhea or Vomiting 
ï‚· Active Eating Disorder 
 Current use of steroids 20.
 Active drug/alcohol dependence or abuse history.   21.
 Decisionally impaired patients. 22.
 Gender/Minority/Pediatric Inclusion for Research 4.[ADDRESS_1188357] cancer are eligible for the study. Patients can be recruited from the PI, 
co-investigatorsâ€™ or referring physicianâ€™s clinical practices. We have designed a 
brochure to try and help with patient recruitment. This brochure is attached in the 
Appendix VIII Section. Potential study subject should be referred to PI [INVESTIGATOR_853726]/research associate. Appropriate laboratory or diagnostic 
testing necessary to meet any noted inclusion or exclusion criteria will be ordered 
   
 
12G.616 Protocol v4.2 (04Jan2016)  22 
through the recruiting physician. PI [INVESTIGATOR_853727]/research associate will screen and determine the final eligibility of the subject 
for enrollment.  
 Early Withdrawal of Subjects 4.[ADDRESS_1188358] the right to withdraw from the study at any 
time for any reason, without prejudice to their medical care. The investigator also 
has the right to withdraw patients from the study for any of the following reasons: 
1. Intercurrent illness 
2. Occurrence of an unacceptable adverse event such as a Grade â‰¥ 4 toxicity or â‰¥ 20% 
weight 
3. Missing more than [ADDRESS_1188359] 
5. Protocol violations based on the judgment of PI 
6. Non-compliance 
7. Administrative reasons 
8. Failure to return for follow- up 
9. General or specific changes in the patientâ€™s condition unacceptable for further 
treatment in the judgment of the investigator 
10. Patients may withdraw from the study voluntarily at any time; however, the Principal 
Investigator [INVESTIGATOR_853728]. 
11. Radiation toxicity becomes too severe and the patient can no longer tolerate 
consecutive radiation treatments as determined by [CONTACT_167752]. 
12. Patients are hospi[INVESTIGATOR_853729]. 
Particularly admissions lasting longer than 4 days. 
13. Patients develop any of the exclusionary conditions during treatments including: 
hepatic insufficiency, diabetes, disorders requiring corticosteroid treatment, renal 
failure or pregnancy. 
14. Patients become sexually active and do not wish to use contraception or patients 
discontinue previous method of contraception and remain sexually active. 
At the time of withdrawal, all study procedures outlined for the End of Study visit 
should be completed. The primary reason for a patientâ€™s withdrawal from the study 
is to be recorded in the source documents. 
 Data Collection and Follow-up for Withdrawn Subjects 4.5.[ADDRESS_1188360] who is withdrawing needs to state whether he/she wishes to provide 
continued follow-up and further data collection subsequent to withdrawal from the 
interventional portion of the study.  
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188361]â€™s withdrawal from the study 
will included in the study analysis. However, the subjectâ€™s clinical data will not be 
used for dose escalation determination. 
 Study Drug /Therapy  5
 Description 5.1
Baseline caloric intake will be assessed by [CONTACT_853752] 7 to 10 days prior to 
radiation treatment planning. Recommendations by [CONTACT_853756] 25% and the patient will begin this diet immediately 
after the planning session and for a minimum of 2 weeks before starting radiation. The 
patient will then remain on this calorically restricted diet as measured by [CONTACT_853757] a minimum of 2 weeks after the 
completion of the radiation course. This is done to ensure that he patients undergo 
caloric restriction for a minimum of 10 weeks +/-1-2 weeks. 
Restriction of calories is the primary objective of dietary modification and will be 
tailored to each patient by [CONTACT_853758]. Diet guidelines and compliance will be reviewed 
at weekly on-treatment visits by [CONTACT_853759]. 
 Treatment Regimen 5.2
 Prior to Radiation: 5.2.1
Caloric restriction to 75% of normal calorie intake will begin when patients present 
for radiation treatment planning. Prior to this, patients will have recorded their daily 
intake in food journals for 2 weeks. Patients will remain on this calorically restricted 
diet until completion of radiation treatment for a total of 10 weeks.  
Restriction of calories is the primary objective of dietary modification; however, to 
patients will be encouraged to maintain adequate nutrient intake. Diet guidelines 
and adherence will be enforced at weekly on-treatment visits by [CONTACT_853760]. 
 Risks of Caloric Restriction 5.3
Likely (>10%) 
ï‚· Weight loss 
ï‚· Fatigue 
ï‚· Irritability 
   
 
12G.616 Protocol v4.2 (04Jan2016)  24 
Possible 
ï‚· Decreased bone mineral density 
ï‚· Decreased muscle mass and strength 
ï‚· Dehydration 
ï‚· Constipation 
ï‚· Depression 
ï‚· Fainting 
Rare (<2%) 
ï‚· Cholelithiasis 
ï‚· Reversible amenorrhea 
ï‚· Malnutrition 
ï‚· Reduced sex drive 
ï‚· Acidosis 
 Method for Assigning Subjects to Treatment Groups 5.4
As a feasibility trial, all patients will be expected to be on treatment as defined by 
[CONTACT_139492], radiation therapy and nutritional counseling.  
 Preparation and Administration of Study Drug/Therapy 5.[ADDRESS_1188362] to maintain a weekly 25% reduction of 
caloric intake for 80% of the logged events in order to be considered compliant for this 
trial. 
See Appendix IX for printed food diary and access to online food diary. 
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188363] -
lumpectomy  Day All All All 1    2    3    4    5     6    7  All 
Diet Normal  Normal  CR Diet  Continue CR Diet  CR Diet  
Radiation  None  Simulation  None   None  
 Study Visit Schedule 6.2
 Screening 6.2.1
Eligibility of patients will be verified based on clinical staging and any need for 
adjuvant chemotherapy as well as previously stated eligibility criteria. Those 
eligible patients will receive detailed information about the study including a step-
by-step outline of proposed treatment including radiation therapy and diet 
modification. Patients will be informed of possible risks and benefits. Informed 
consent will be obtained from patients. A full history and physical examination will 
be performed on consented patients. Baseline weight and BMI will be taken. In 
addition, blood will be drawn for eligibility measurements of beta-hCG if 
appropriate .  
 Phase Iâ€”Pre-treatment 6.2.2
Visit 1:  Patients will report to the Radiation Oncology Department for radiation 
treatment planning to include CT simulation. Food diaries from the previous 7- 10 
days will be collected and analyzed to create a diet plan for each patient. 
Integrative medicine will meet with patients to counsel them on lifestyle changes 
and behavioral aspects of dietary modification. Dietary counselors will give patients 
guidelines for dietary modification including the appropriate amount of calories that 
each patient should be receiving and what kinds of foods they should avoid or eat 
more of. Nutritional counseling will be done using behavioral cues to encourage 
adherence (see Appendix V for worksheets). Patients will be instructed to begin 
their new diet starting at this visit and to continue logging foods into their journals. 
They will complete the journal daily. Patients will undergo a focused examination to 
assess initial breast appearance and texture for comparison as patients receive 
radiation therapy. Fasting blood will be drawn for baseline laboratories at this visit. 
Clinical measurements will include CBC w/diff, CMP, HbA1c, IGF-1, adiponectin, 
leptin, estradiol, triglycerides, insulin, ESR. Separately, blood samples will also be 
   
 
12G.616 Protocol v4.2 (04Jan2016)  26 
analyzed for the following: IGF-1R, IRS-[ADDRESS_1188364]-B form as well as a baseline fatigue assessment using the 
PROMIS cancer fatigue short form (see appendix XI). Weight, height, vital signs, 
bioimpedance and caliper measurements will be done. 
Phone Intervention:  Patients will be contact[CONTACT_853761] a week during the 
time they are keepi[INVESTIGATOR_853730]. 
Visit 2:  Week 1 or day 7 (Â±2 day) of diet. Weight will be measured and vital signs 
will be taken. Food diary from previous week to be collected, as well as 24hr recall 
of diet. 
Visit 3:  Week 2 of diet. Weight will be measured and vital signs will be taken. Food 
diary from previous week to be collected, as well as 24hr recall of diet. 
 Phase IIâ€”Visits During Radiation Treatment 6.2.3
Visit 4-9:  Patients will be monitored for acute radiation toxicity including skin 
changes and desquamation. Patients will be questioned and examined to ensure 
general health and will be reassured about radiation-related side effects. Patients 
will turn in their food diary from the previous week and dietary counselors will 
review these with the patients to determine how they can continue to comply with 
dietary modification. At each visit, a 24hr recall of diet will be asked of the patient 
and compared with the diet journal to determine the self reporting accuracy. Each 
week during this period, patients will be counseled on their diet and given 
behavioral modification lessons corresponding to specific weeks in the diet (see 
Appendix V for worksheets). Weight will be taken at weeks 3, [ADDRESS_1188365]-B psychosocial assessment will be given at visit 7along with the 
PROMIS cancer fatigue short form. In addition, at visit 7 (week 5 of diet) patients 
will have a fasting blood draw done for insulin level.  
Radiation will be planned to be administered 5 days a week, Monday through 
Friday. Radiation is given for approximately 6-6.5 weeks or 30- 33 treatments. 
 Phase IIIâ€”Post Radiation Treatment 6.2.4
Visit 10:  Week 9 of diet,for scheduling purposes. Weight and vital signs will be 
measured. Patients will be monitored for acute radiation toxicity including skin 
changes and desquamation. Patients will turn in their food diary from the previous 
week and dietary counselors will review these with the patients to determine how 
they can continue to comply with dietary modification. A 24hr recall of diet will be 
asked of the patient and compared with the diet journal to determine the self-
reporting accuracy. Patients will be counseled on behavioral modification for the 
final week of their diet (see Appendix V for worksheet). Weight and vital signs will 
be measured. 
   
 
12G.616 Protocol v4.2 (04Jan2016)  27 
Visit 11:  Week 10 of diet, +/- 3-[ADDRESS_1188366] day of diet ; 
Fasting blood draw to be done for CBC, basic metabolic panel, hemoglobin A1C, 
triglycerides, insulin, IGF-1, erythrocyte sedimentation rate (ESR), adiponectin, 
leptin and estradiol. Separately, blood will be analyzed for IRS-1, IGF-1R. Weight 
and vital signs will be measured. Conclusion bioimpedance and caliper 
measurements will be taken. Patients will be monitored for acute radiation toxicity 
including skin changes and desquamation. Patients will turn in their food diary from 
the previous week and dietary counselors will review these with the patients to 
determine how they can continue to comply with dietary modification. A 24hr recall 
of diet will be asked of the patient and compared with the diet journal to determine 
self-reporting accuracy. Patients will complete the FACT-B psychosocial evaluation 
as well as the PROMIS cancer fatigue short form.  
Visit 12: 4 wee ks after completion of diet.  Fasting blood draw to be done for CBC, 
basic metabolic panel, hemoglobin A1C, triglycerides, insulin, IGF -1, erythrocyte 
sedimentation rate (ESR), adiponectin, leptin and estradiol. Separately, blood will 
be analyzed for IRS -1, IGF-1R. Weight, bioimpedence, caliper measurements and 
vital signs will be measured.  Patients will be monitored for acute radiation toxicity 
including skin changes and desquamation. Patients will turn in their food diary from 
the last diet week. FACT -B and PROMIS cancer fatigue short form will be 
administered.  
 Study Flowchart 6.[ADDRESS_1188367] RT  Follow -up 
 Screening  Surgery  Sim Week of Caloric Restriction Diet   
    1 2 3 4 5 6 7 8 9 10  
Visit Number  0 1 2 3 
D7 4 
D14 5 6 7 8 9 1
0 11 12 
Las
t 13 
Informed 
Consent  X              
Background Info 
(demographics, 
meds, medical 
history)  X              
Inclusion/Exclus
ion Criteria  X              
Vital Signs    X X X X X X X X X X X X 
H&P; 
Performance 
Status  X              
Focused 
Physical    X   X X X X X X   X 
Weight, BMI  X  X X  X  X  X   X X 
Caliper 
Measurements, 
Bioimpedance    X          X X 
 
   
 
12G.616 Protocol v4.2 (04Jan2016)  28 
Clinical Labs: 
CBC w/diff, 
CMP, HbA1c  
Serum: IGF -1, 
adiponectin, 
leptin, estradiol, 
triglycerides,  
fasting insulin, 
ESR   X          X X 
 
Fasting insulin 
level        X       
               
Other Labs:  
IGF-1R, IRS -1,    X          X X 
FACT -B 
Psychosocial 
Evaluation    X     X     X X 
 
PROMIS cancer 
fatigue short 
form   X     X     X X 
Specimen sent 
to Pathology for 
histologic e xam 
andER, PR, 
HER2   X             
Dietary 
Counseling  X  X   X X X X X X    
Behavioral 
Counseling     X  X X X X X X X   
Food Diary 
Collected    X X X X X X X X X X X  
Acute Toxicity 
Assessment    X   X X X X X X X X X 
 
Key:  H&P=Full history and physical exam 
 Sim=Radiation simulation planning session 
 RT=Radiation Therapy 
 D7=Day 7 of caloric restriction diet; D14=Day [ADDRESS_1188368]=Final day of caloric restriction diet 
 Radiation Treatment 6.[ADDRESS_1188369]: 50 Gy in 25 fractions of 2 Gy.  [IP_ADDRESS]
 Lumpectomy PTV Cavity: Total dose will be 10- 16 Gy in 5-8 fractions  [IP_ADDRESS]
 Total radiation dose 60- 66Gy [IP_ADDRESS]
 Technical Factors 6.4.2
 The patient may be treated by [CONTACT_853762]. Fields [IP_ADDRESS]
and treatment type will be up to the discretion of the treating radiation 
oncologist and may include but is not limited to 3D-RT, IMRT and en face.  
   
 
12G.616 Protocol v4.2 (04Jan2016)  29 
 The guidelines for IMRT in this trial will conform to the policies set by [CONTACT_941] [IP_ADDRESS]
Advanced Technology Consortium (ATC) and the National Cancer Institute 
(NCI) http://atc.wustl.edu/home/NCI/NCI_IMRT_Guidelines.html 
 Megavoltage photon beams with energies â‰¥6 MV and megavoltage electron [IP_ADDRESS]
beams are required. 
 Localization, Simulation, and Immobilization 6.4.3
 Simulation and treatment may be performed with the patient in the supi[INVESTIGATOR_283958] [IP_ADDRESS]
prone position. 
 Patients should be optimally positioned with immobilization devices at the [IP_ADDRESS]
discretion of the treating physician such as alpha cradle casts, breast 
boards, wing boards. 
 Methods to minimize the cardiac exposure to RT like heart block, gating or [IP_ADDRESS]
breathhold are allowed at the discretion of the treating physician 
 For large-breasted patients, including those with a large inframammary skin [IP_ADDRESS]
fold, devices to improve positioning of the breast are permissible. 
 A treatment planning CT scan in the treatment position will be required to [IP_ADDRESS]
define the tumor bed for boost. 
 The CT required for generation of a virtual plan with 3DCRT or [IP_ADDRESS].[ADDRESS_1188370] be placed on external landmarks at the [IP_ADDRESS].[ADDRESS_1188371] data-set. These markers should identify: 1) The lumpectomy 
incision 2) Additional markers to define the clinical borders of 
tangent fields (e.g. based on the palpable breast tissue and boney 
landmarks). 
 The CT should extend cephalad to start at or above the mandible [IP_ADDRESS].3
and extend sufficiently caudally (or inferiorly) to the inframammary 
fold to encompass the entire lung volume. A CT scan image 
thickness of â‰¤0.5 cm should be employed. 
 External skin localizing marks, which may include permanent [IP_ADDRESS].4
tattoos, are recommended for radiation daily localization and set- up 
accuracy. 
 Treatment Planning/Target Volumes 6.4.4
 Planning isodose lines will be chosen by [CONTACT_35425].  [IP_ADDRESS]
 Target Volumes and Normal Structures [IP_ADDRESS]
 Lumpectom y CTV: Contour using all available clinical and radiographic [IP_ADDRESS]
information including the excision cavity volume, architectural distortion, 
lumpectomy scar, seroma and/or extent of surgical clips (clips are strongly 
recommended). Patients without a clearly identifiable lumpectomy bed do 
not need a boost. Lumpectomy CTV volume will be expanded by 1.5 to 2cm 
at the physicians discretion and the expanded volume (Lumpectomy PTV) 
will be treated. 
 Ipsilateral lung. This may be contoured with auto-segmentation with manual [IP_ADDRESS]
   
 
12G.616 Protocol v4.2 (04Jan2016)  30 
verification. 
 Contralateral lung. This may be contoured with auto-segmentation with [IP_ADDRESS]
manual verification 
 Heart : The heart should be contoured beginning just inferior to the level in [IP_ADDRESS]
which the pulmonary trunk branches into the left and right pulmonary arteries 
(PA). Above the PA, none of the hearts 4 chambers are present. All the 
mediastinal tissue below this level should be contoured, including the great 
vessels (ascending and descending aorta, inferior vena cava). The heart 
should be contoured on every contiguous slice thereafter to its inferiormost 
extent near the diaphragm. If one can identify the esophagus, this structure 
should be excluded from the heart. One need not include pericardial fat, if 
present. Contouring along the pericardium itself, when visible, is appropriate. 
 Treatment Verification 6.[ADDRESS_1188372] treatment:  6.5.[ADDRESS_1188373] be obtained and approved by a physician prior to initiation of treatment. 
 Subsequent images or films:  6.5.[ADDRESS_1188374] be obtained prior to fraction number 
5 and every 5 fractions subsequently. The imaging modality and process should be 
performed based on the institutional guidelines. 
 Radiation Therapy Adverse Events 6.6
All Radiation Therapy AEs will be scored according to the NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 4 
Short Term: Fatigue is an anticipated systemic reaction to radiation treatment. Skin 
erythema, desquamation, breast edema, breast tenderness and myositis are potential 
local reactions. 
Long Term: Long term effects possibly include radiation pneumonitis, rib fractures, 
second malignancy and for left-sided lesions cardiac complications 
 STATISTICAL PLAN 7
 Sample Size Determination 7.1
The study will enroll a total of 90 patients. For Phase 1, with a sample size of 40 , 
the study has 83% power to establish that adherence is higher than 60%, assuming 
that true adherence will be 80% or greater (one-sided exact binomial test with alpha 
0.05). 
   
 
12G.616 Protocol v4.2 (04Jan2016)  31 
 Statistical Methods 7.2
Primary endpoint (adherence). We will compute the proportion of patients who are 
adherent to the diet restriction (as defined in section 3.2), along with a 95% exac t 
confidence interval. We will also use an exact binomial test (with a one-sided alpha of 
0.05) to test whether adherence is greater than 60%.  
Aim 1b. We will compute the proportion of patients with toxicity, along with a 95% 
exact confidence interval. Our institutionâ€™s historical toxicity rate among similar 
patients is about 80% and we aim to prove that the dietary intervention is non-inferior 
with an absolute margin of 10%, using an exact binomial test. With a total sample size 
of 90 and assuming that true toxicity will be 80% or lower, we have 82% power (with 
one-sided alpha of 0.05). 
Secondary endpoints. The change in body fat measurement between baseline and the 
end of the study will be analyzed via a paired t-test. Weight changes over time will be 
assessed by [CONTACT_853763] a function of time (baseline, diet weeks 1, 3, 5, 7, and 
10) via mixed-effects regression.  The patterns of change over time in vital signs, 
insulin and other clinical labs, serum markers, and psycho-social outcomes (FACT-B) 
will also be analyzed similarly. If some of these measures are skewed, we will 
transform them (e.g., log) before the analyses. Finally, local recurrence, distant 
metastases, progression free survival, and overall survival will be analyzed via 
survival methods, specifically the Kaplan-Meier method and the logrank test. If 
sufficient events occur, we may assess the impact of various patient and 
clinical/treatment variables on these outcomes via Cox proportional hazards 
regression.  
Local recurrence, progression free survival, distant metastases and overall survival 
will be assessed and compared with historic controls using the Kaplan Meier method. 
Local recurrence, progression free survival, distant metastases and overall survival 
will be measured from the date of study enrollment to time of event. 
 Subject Population(s) for Analysis 7.[ADDRESS_1188375] 4 food diaries per week 
during the diet modification phase will be used for analysis. 
 Safety and Adverse Events 8
 Definitions 8.1
 Adver se Event 8.1.1
An adverse event  (AE) is any symptom, sign, illness or experience that develops 
or worsens in severity during the course of the study.  Intercurrent illnesses or 
injuries should be regarded as adverse events.  Abnormal results of diagnostic 
procedures are considered to be adverse events if the abnormality: 
ï‚· results in study withdrawal 
ï‚· is associated with a serious adverse event 
   
 
12G.616 Protocol v4.2 (04Jan2016)  32 
ï‚· is associated with clinical signs or symptoms 
ï‚· leads to additional treatment or to further diagnostic tests 
ï‚· is considered by [CONTACT_338913] 8.1.2
Adverse events are classified as serious or non-serious.   
A serious adverse event  is any AE that is:  
ï‚· fatal 
ï‚· life-threatening 
ï‚· requires or prolongs hospi[INVESTIGATOR_4408] 
ï‚· results in persistent or significant disability or incapacity 
ï‚· a congenital anomaly or birth defect 
ï‚· an important medical event 
Important medical events are those that may not be immediately life threatening, 
but are clearly of major clinical significance. They may jeopardize the subject, and 
may require intervention to prevent one of the other serious outcomes noted 
above.  For example, drug overdose or abuse, a seizure that did not result in in-
patient hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in an emergency 
department would typi[INVESTIGATOR_15355].  
All adverse events that do not meet any of the criteria for serious should be 
regarded as non-serious adverse events.  
 Adverse Event Reporting Period  8.1.[ADDRESS_1188376] administration of study treatment.   
 Preexisting Condition 8.1.4
A preexisting condition is one that is present at the start of the study.  A preexisting 
condition should be recorded as an adverse event if the frequency, intensity, or the 
character of the condition worsens during the study period.  
 General Physical Examination Findings 8.1.5
At screening, any clinically significant abnormality should be recorded as a 
preexisting condition.  At the end of the study, any new clinically significant 
findings/abnormalities that meet the definition of an adverse event must also be 
recorded and documented as an adverse event.   
 Post-study Adverse Event 8.1.[ADDRESS_1188377] to follow-up, or the adverse event is 
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188378] to report any subsequent event(s) that the subject, or the subjectâ€™s 
personal physician, believes might reasonably be related to participation in this 
study.  The investigator should notify the study sponsor of any death or adverse 
event occurring at any time after a subject has discontinued or terminated study 
participation that may reasonably be related to this study.  The sponsor should also 
be notified if the investigator should become aware of the development of cancer or 
of a congenital anomaly in a subsequently conceived offspring of a subject that has 
participated in this study.   
 Abnormal Laboratory Values 8.1.7
A clinical laboratory abnormality should be documented as an adverse event if any 
one of the following conditions is met:   
ï‚· The laboratory abnormality is not otherwise refuted by a repeat test to confirm the 
abnormality 
ï‚· The abnormality suggests a disease and/or organ toxicity 
ï‚· The abnormality is of a degree that requires active management; e.g. change of 
dose, discontinuation of the drug, more frequent follow-up assessments, further 
diagnostic investigation, etc. 
 Hospi[INVESTIGATOR_059], Prolonged Hospi[INVESTIGATOR_146706] 8.1.8
Any adverse event that results in hospi[INVESTIGATOR_853731] a serious adverse event unless specifically 
instructed otherwise in this protocol.  Any condition responsible for surgery should 
be documented as an adverse event if the condition meets the criteria for and 
adverse event.  
Neither the condition, hospi[INVESTIGATOR_059], prolonged hospi[INVESTIGATOR_059], nor surgery are 
reported as an adverse event in the following circumstances: 
ï‚· Hospi[INVESTIGATOR_5110] a preexisting condition.  Surgery should not be reported as an 
outcome of an adverse event if the purpose of the surgery was elective or diagnostic 
and the outcome was uneventful. 
ï‚· Hospi[INVESTIGATOR_413722]. 
ï‚· Hospi[INVESTIGATOR_16458], unless it is a worsening or increase in frequency of hospi[INVESTIGATOR_85367]. 
 Recording of Adverse Events 8.[ADDRESS_1188379] seek information on adverse 
events by [CONTACT_5147], as appropriate, by [CONTACT_5148].  Information on all 
adverse events should be recorded immediately in the source document, and also in 
the appropriate adverse event module of the case report form (CRF).  All clearly 
related signs, symptoms, and abnormal diagnostic procedures results should be 
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188380] be followed 
up to determine the final outcome.  Any serious adverse event that occurs after the 
study period and is considered to be possibly related to the study treatment or study 
participation should be recorded and reported immediately. 
 Unblinding Procedures 8.3
This is single arm study. There is no unblinding procedure. 
 Stoppi[INVESTIGATOR_1869]  8.4
There will be no formal interim analyses for purposes of stoppi[INVESTIGATOR_87545]. 
However, descriptive analyses for monitoring accrual and study implementation will be 
carried out throughout the study. 
 Data and Safety Monitoring Plan 8.5
It is the responsibility of the Principal Investigator [INVESTIGATOR_344899]/her site.  This safety monitoring will include careful assessment and appropriate 
reporting of adverse events as noted above, as well as the compliance and 
implementation of the KCC data and safety-monitoring plan.  Medical monitoring will 
include a regular assessment of the number and type of serious adverse events by 
[CONTACT_233743]. 
 Medical Monitoring and AE/SAE Reporting 8.5.1
A Medical Monitor is assigned to this study at the Thomas Jefferson University.  
This is a physician/pharmacist who is not directly involved in the trial, and is not 
currently collaborating with the sponsor/investigator on any other trial.  The role of 
the Medical Monitor is to review all reportable AEs/SAEs (in real-time) including 
grading, toxicity assignments, non-reportable AEs (quarterly), protocol 
violations/deviations, as well as all other safety data and activity data observed in 
the ongoing clinical trial occurring at Thomas Jefferson University . The Medical 
Monitor may recommend reporting of adverse events and relevant safety data, and 
may also recommend suspension or termination of the study to the DSMC and TJU 
IRB.   
Every KCC investigator initiated protocol includes requirements for reporting of 
adverse events based on CTC 4.0. All events are reported to the IRB and Medica l 
Monitor using a password protected web-site. In addition all unexpected and 
serious adverse events (SAEs) are reported to the TJU IRB and to the Food and 
Drug Administration (FDA) if applicable. The investigator is required to submit all 
unexpected and serious adverse events to the TJU IRB and the Medical Monitor 
within the timeframes outlined in the below table. All AE/SAEs will be reported to 
   
 
12G.616 Protocol v4.2 (04Jan2016)  35 
the DSMC at the quarterly DSMC review meetings; however, if the Medical Monitor 
determines corrective action is necessary, an â€œad hocâ€ DSMC meeting will be 
called. Fatal adverse events related to treatment which are unexpected must 
be reported within 24 hours to the TJU IRB and the DSMC. Fatalities not 
related to the study drug/device must be reported within 5 days. A summary of 
the reporting requirements for KCC investigator initiated Phase I and Phase II 
studies are presented below.  
 
 Grade 1  Grade 2  Grade 2  Grade 3  Grade 3  Grades 4 
and 5  
 Unexpected 
and 
Expected  Unexpected  Expected  Unexpected 
with 
Hospi[INVESTIGATOR_5186] n Unexpected 
without 
Hospi[INVESTIGATOR_5186]
n Expected 
with 
Hospi[INVESTIGATOR_5186]
n Expected 
without 
Hospi[INVESTIGATOR_853732]
d and 
Expected  
Unrelated  
Unlikely  Reviewed at 
Quarterly 
DSMC 
Meeting and 
IRB Annual 
Review  Reviewed at 
Quarterly 
DSMC 
Meeting and 
IRB Annual 
Revie w Reviewed 
at 
Quarterly 
DSMC 
Meeting 
and IRB 
Annual 
Review  5 Working 
Days  Reviewed at 
Quarterly 
DSMC 
Meeting and 
IRB Annual 
Review  5 Working 
Days  Reviewed at 
Quarterly 
DSMC 
Meeting and 
IRB Annual 
Review  Phase 1 -             
48 Hours   
(Death: 24 
Hours)  
 
Phase 2 -            
5 Working 
Days          
Possible  
Probable  
Definite  Reviewed at 
Quarterly 
DSMC 
Meeting and 
IRB Annual 
Review  5 working 
days Reviewed 
at 
Quarterly 
DSMC 
Meeting 
and IRB 
Annual 
Review  48 Hours    
(Death: 24 
Hours)  Phase 1 -             
48 Hours   
 
Phase 2 -              
5 Working 
Days  48 Hours    
(Death: 24 
Hours)  Reviewed at 
Quarterly 
DSMC 
Meeting and 
IRB Annual 
Review  Phase 1 
and Phase 
2 -             
48 Hours         
(Death: 24 
Hours)  
 
**NOTE: This table is based on the NCI AE/SAE reporting Guidelines and the TJU 
IRB Policy and Procedures. Please follow the individual protocol AE/SAE reporting 
guidelines if more stringent reporting procedures are specified. 
 Data and Safety Monitoring Committee 8.5.2
Data and Safety Monitoring Committee (DSMC) is the Data and Safety Monitoring 
Board (DSMB) for the KCC. The DSMC is a multidisciplinary committee charged 
with overseeing the monitoring of safety of participants in clinical trials, and the 
conduct, progress, validity, and integrity of the data for all clinical trials at the 
Thomas Jefferson University KCC. The committee meets quarterly to review the 
progress and safety of all active research protocols that are not monitored by 
[CONTACT_233745]. 
ï‚· The DSMC meets quarterly. Additional DSMC meetings are scheduled based on the 
nature and number of trials being monitored over a specified time period. The DSMC 
meets (by [CONTACT_15498]) within 24 hours following the notification of an unexpected 
adverse event felt to be related to the study drug.  
ï‚· Prior to each DSMC meeting, each board member, is provided a printout of all 
reported AEs and SAEs occurring during the reporting period for this clinical trial. 
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188381] of the trial. DSMC members 
are provided with the principal investigatorâ€™s assessment, a written report 
summarizing adverse events, safety data, and activity data observed during the 
specified time period described in each protocol, as well as recommendations from 
the Medical Monitor. A review of outcome results (response, toxicity and adverse 
events) and factors external to the study (such as scientific or therapeutic 
developments) is discussed, and the Committee votes on the status of each study.  
ï‚· A summary of the boardâ€™s action is sent to each investigator, the CCRRC and TJU 
IRBs. The DSMC actions may include recommendations/requirements that will lead 
to improved patient safety and/or efficacy, significant benefits or risks that have 
developed, or other changes determined to be necessary. The DSMC may also take 
note of slow accrual or lack of scientific progress, and refer such issues to the 
CCRRC. The DSMC provides the investigator with the rationale for any decision 
made.  
 Data Handling and Record Keepi[INVESTIGATOR_007] [ADDRESS_1188382] of 1996 
(HIPAA).  Those regulations require a signed subject authorization informing the 
subject of the following:  
ï‚· What protected health information (PHI) will be collected from subjects in this study 
ï‚· Who will have access to that information and why 
ï‚· Who will use or disclose that information 
ï‚· The rights of a research subject to revoke their authorization for use of their PHI.  
In the event that a subject revokes authorization to collect or use PHI, the investigator, 
by [CONTACT_5151], retains the ability to use all information collected prior to the revocation 
of subject authorization.  For subjects that have revoked authorization to collect or use 
PHI, attempts should be made to obtain permission to collect at least vital status (i.e. 
that the subject is alive) at the end of their scheduled study period. 
 Source Documents 9.2
Source data is all information, original records of clinical findings, observations, or 
other activities in a clinical trial necessary for the reconstruction and evaluation of the 
trial. Source data are contained in source documents.   Examples of these original 
documents, and data records include: hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory notes, memoranda, subjectsâ€™ diaries or evaluation checklists, pharmacy 
dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_5117], microfiches, 
photographic negatives, microfilm or magnetic media , x-rays, subject files, and 
records kept at the pharmacy, at the laboratories, and at medico-technical 
departments involved in the clinical trial. 
   
 
12G.616 Protocol v4.2 (04Jan2016)  37 
 Case Report Forms 9.3
The study case report form (CRF) is the primary data collection instrument for the 
study. All data requested on the CRF must be recorded. All missing data must be 
explained. If a space on the CRF is left blank because the procedure was not done or 
the question was not asked, write â€œN/Dâ€. If the item is not applicable to the individual 
case, write â€œN/Aâ€. All entries should be printed legibly in black ink . If any entry error 
has been made, to correct such an error, draw a single straight line through the 
incorrect entry and enter the correct data above it. All such changes must be initialed 
and dated. DO NOT ERASE OR WHITE OUT ERRORS. For clarification of illegible or 
uncertain entries, print the clarification above the item, then initial and date it. 
CRFs are found in the Appendix VII.  
 Records Retention 9.4
It is the investigatorâ€™s responsibility to retain study essential documents for at least [ADDRESS_1188383] elapsed since the trial began. 
 STUDY MONITORING, AUDITING, AND INSPECTING 10
 Study Monitoring Plan 10.1
The investigator will allocate adequate time for monitoring activities. The Investigator 
will also ensure that the medical monitor or other compliance or quality assurance 
reviewer is given access to all the above noted study-related documents and study 
related facilities (e.g. pharmacy, diagnostic laboratory, etc.), and has adequate space 
to conduct the monitoring visit. 
 Auditing and Inspecting 10.2
The investigator will permit study-related monitoring, audits, and inspections by [CONTACT_5040], the funding sponsor, government regulatory bodies, and University compliance 
and quality assurance groups of all study related documents (e.g. source documents, 
regulatory documents, data collection instruments, study data etc.). The investigator 
will ensure the capability for inspections of applicable study-related facilities (e.g. 
pharmacy, diagnostic laboratory, etc.). 
Participation as an investigator in this study implies acceptance of potential inspection 
by [CONTACT_137713]. 
 Independent External and Internal Audits  10.2.[ADDRESS_1188384] achieved 10% of target accrual. 
However, a study can be audited at any time based on recommendations by [CONTACT_941] 
   
 
12G.616 Protocol v4.2 (04Jan2016)  38 
IRB, DSMC, CCRRC and/or the Director of Clinical Investigations, KCC. Studies 
are re-audited once they have achieved 50% of target accrual. Special audits may 
be recommended by [CONTACT_1201], DSMC or CCRRC based on prior findings, 
allegations of scientific misconduct and where significant irregularities are found 
through quality control procedures. Any irregularities identified as part of this 
process would result in a full audit of that study.  
In addition to the audits at 10 and 50%, the CRMO randomly audits at least [ADDRESS_1188385] a bi-annual basis, to verify that there is a signed and dated 
patient consent form, the patient has met the eligibility criteria, and that SAEs are 
documented and reported to the TJU IRB.  
All audit reports are submitted to the DSMC for review and action (when 
appropriate). A copy of this report and recommended DSMC action is sent to the 
CCRRC and TJU IRB. The committee regards the scientific review process as 
dynamic and constructive rather than punitive. The review process is designed to 
assist Principal Investigators in ensuring the safety of study subjects and the 
adequacy and accuracy of any data generated. The TJU IRB may, based on the 
DSMC and auditorâ€™s recommendation, suspend or terminate the trial.  
 Ethical Considerations 11
This study is to be conducted according to US and international standards of Good 
Clinical Practice (FDA Title 21 part 312 and International Conference on Harmonization 
guidelines), applicable government regulations and Institutional research policies and 
procedures. 
This protocol and any amendments will be submitted to a properly constituted 
independent Institutional Review Board (IRB), in agreement with local legal 
prescriptions, for formal approval of the study conduct.  The decision of the IRB 
concerning the conduct of the study will be made in writing to the investigator before 
commencement of this study.   
All subjects for this study will be provided a consent form that is compliant with local and 
federal regulations, describing this study and providing sufficient information for subject s 
to make an informed decision about their participation in this study.  See Attachment for 
a copy of the Subject Informed Consent Form.  This consent form will be submitted with 
the protocol for review and approval by [CONTACT_14884].  The formal consent of a 
subject, using the IRB-approved consent form, must be obtained before that subject is 
submitted to any study procedure.  This consent form must be signed by [CONTACT_468272], and the investigator-designated research professional 
obtaining the consent.  
 Study Finances 12
 Funding Source 12.1
This study is financed through a generous pi[INVESTIGATOR_853733] 
   
 
12G.616 Protocol v4.2 (04Jan2016)  39 
Richmond. It is also financed in part by [CONTACT_853764]â€™s NCI Cancer 
Center Support Grant P30 CA56036. 
 Conflict of Interest 12.[ADDRESS_1188386] with this study (patent ownership, 
royalties, or financial gain greater than the minimum allowable by [CONTACT_1385], etc.) 
must have the conflict reviewed by a properly constituted Conflict of Interest 
Committee with a Committee-sanctioned conflict management plan that has been 
reviewed and approved by [CONTACT_28833].  All 
Jefferson University Investigators will follow the TJU Conflicts of Interest Policy for 
Employees (107.03). 
 Publication Plan 13
All investigators involved in the portion of the trial being published will review 
manuscripts prior to publication. The Principal Investigator [INVESTIGATOR_853734].  
 Specimen Banking 14
Tissue and blood specimen banking is included in this protocol. Tissue and blood 
specimens will be stored in a secure -70Â° freezer in the Bodine Cancer Center.  
Specimen collections will be performed on consented patients. Please see Appendix VI 
for detailed information on schedule, amount, storage and shippi[INVESTIGATOR_140112]. 
 References 15
1. Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic 
and molecular mechanisms. Trends Pharmacol Sci. Feb;31(2):89- 98. 
2. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie 
restriction, aging, and cancer prevention: mechanisms of action and 
applicability to humans. Annu Rev Med. 2003;54:131-152. 
3. Rous P. The influence of diet on transplanted and spontaneous mouse 
tumors. J. Exp. Med. 1909;20(431). 
4. Tannenbaum A. Effects of Varying Caloric Intake Upon Tumor Incidence 
and Tumor Growth . Annals of the New Yrok Acedemy of Sciences. 15 Dec 
2006 2006;49(1). 
5. Berrigan D, Perkins SN, Haines DC, Hursting SD. Adult-onset calorie 
restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. 
Carcinogenesis. May 2002;23(5):817-822. 
6. Zhu Z, Jiang W, Thompson HJ. Effect of energy restriction on tissue size 
regulation during chemically induced mammary carcinogenesis. 
Carcinogenesis. Sep 1999;20(9):1721-1726. 
7. Lok E, Scott FW, Mongeau R, Nera EA, Malcolm S, Clayson DB. Calorie 
restriction and cellular proliferation in various tissues of the female Swiss 
Webster mouse. Cancer Lett. May 15 1990;51(1):67-73. 
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188387] 11 
1994;91(21):9995-9999. 
9. Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-I receptor 
overexpression mediates cellular radioresistance and local breast cancer 
recurrence after lumpectomy and radiation. Cancer Res. Aug 1 
1997;57(15):3079-3083. 
10. Perer ES, Madan AK, Shurin A, et al. Insulin- like growth factor I receptor 
antagonism augments response to chemoradiation therapy in colon cancer 
cells. J Surg Res. Nov 2000;94(1):1- 5. 
11. Donohoe CL, Doyle SL, Reynolds JV. Visceral adiposity, insulin resistance 
and cancer risk. Diabetol Metab Syndr. 3:12. 
12. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin 
resistance and type 2 diabetes. Nature. Dec 14 2006;444(7121):840- 846. 
13. Lee C , Safdie FM, Raffaghello L , Wei M , Madia F , Parrella E , Hwang 
D, Cohen P , Bianchi G , Longo VD. Reduced levels of IGF- 1 
mediate differential protection of normal and cancer cells in response to 
fasting and improve chemotherapeutic index. Cancer Res.  2010 Feb 
15;70(4):1564-72. 
14. Safdie F , Brandhorst S , Wei M , Wang W , Lee C , Hwang S , Conti PS, Chen 
TC, Longo VD. Fasting enhances the response of glioma to chemo- and 
radiotherapy. PLoS One.  2012;7(9):e44603. 
15. National Institutes of Health. http://www.clincaltrials.gov .  
16. Arguin, H., I. J. Dionne, et al. (2012). Short- and long-term effects of 
continuous versus intermittent restrictive diet approaches on body 
composition and the metabolic profile in overweight and obese 
postmenopausal women: a pi[INVESTIGATOR_799]. Menopause; 19(8): 870-876. 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  41 
 APPENDICES 16
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  42 
Appendix I: Patient Thank You Letter  
 
This is a template to prepare a letter thanking the patient for enrolling in this trial. The 
template is intended as a guide and can be tailored to each patientâ€™s situation. This is to 
increase the awareness of the importance of clinical trials and improve accrual and 
follow-through.  
 
[PATIENT NAME]         [DATE] 
[PATIENT ADDRESS] 
 
Dear [PATIENT SALUTATION], 
 
Thank you for agreeing to take part in this important research study. Many questions 
remain unanswered in cancer. With the help of people like you who participate in clinical 
trials, we will achieve our goal of effectively treating and ultimately curing cancer. 
 
We believe you will receive high quality, complete care. I and my research staff will 
maintain very close contact [CONTACT_56150]. This will allow me to provide you with the best 
care while learning as much as possible to help you and other patients. 
 
On behalf of Thomas Jefferson University , we thank you again and look forward to 
helpi[INVESTIGATOR_56109]. 
 
Sincerely, 
[PHYSICIAN NAME] 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  43 
Appendix II: Karnofsky Performance Scale 
 
Able to carry on normal activity and to work; no 
special care needed.    100   Normal no complaints; no evidence of 
disease.  
90 Able to carry on normal activity; minor 
signs or symptoms of disease.  
80 Normal activity with eff ort; some signs 
or symptoms of disease.  
Unable to work; able to live at home and care for 
most personal needs; varying amount of 
assistance needed.  70 Cares for self; unable to carry on 
normal activity or to do active work.  
[ADDRESS_1188388] of his personal 
needs.  
50 Requires considerable assistance and 
frequent medical care.  
Unable to care for self; requires equivalent of 
institutional or hospi[INVESTIGATOR_10422]; disease may be 
progressing rapi[INVESTIGATOR_375].  40 Disabled; req uires special care and 
assistance.  
30 Severely disabled; hospi[INVESTIGATOR_62420].  
20 Very sick; hospi[INVESTIGATOR_62421]; active supportive treatment 
necessary.  
10 Moribund; fatal processes progressing 
rapi[INVESTIGATOR_375].  
0 Dead  
 
 
 
 
 
 
 
 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  44 
Appendix III: Common Toxicity Criteria Version 4.0 
http://ctep.cancer.gov/reporting/ctc.html  
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  45 
Appendix IV: Visit Schedule  
(please refer to appendix VI for blood specimen banking schedule) 
   
 
12G.616 Protocol v4.2 (04Jan2016)  46 
Appendix V. Behavioral Modification Worksheets 
 
Initially patients will be counseled on eating healthy and dietary modification before 
beginning their diet. They will complete the worksheets labeled â€œBe a Fat Detectiveâ€, 
â€œEating Less Fatâ€ and â€œHealthy Eatingâ€ during this first week. 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  47 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  48 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  49 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  50 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  51 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  52 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  53 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  54 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  55 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  56 
 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  57 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  58 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  59 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  60 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  61 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  62 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  63 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  64 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  65 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  66 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  67 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  68 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  69 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  70 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  71 
Patients will complete this worksheet on environmental cues during week 1 of 
radiation/week 3 of diet. 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  72 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  73 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  74 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  75 
Patients will complete this worksheet on problem solving during week 2 of 
radiation/week 4 of their diet. 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  76 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  77 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  78 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  79 
 
 
 
 
 
  

   
 
12G.616 Protocol v4.2 (04Jan2016)  80 
Patients will complete this worksheet on dining out during week 3 of 
radiation/week 5 of diet. 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  81 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  82 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  83 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  84 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  85 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  86 
 
 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  87 
Patients will complete this worksheet on negative thoughts during week 4 of 
radiation/week 6 of diet. 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  88 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  89 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  90 
 
 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  91 
Patients will complete this worksheet on social cues during week 5 of 
radiation/week 7 of diet. 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  92 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  93 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  94 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  95 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  96 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  97 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  98 
 
 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  99 
Patients will go through the following worksheet during week 6 of radiation/week 
8 of diet. 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  100 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  101 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  102 
 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  103 
Prior to the final week of their diet, patients will go through this worksheet on 
staying motivated. 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  104 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  105 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  106 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  107 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  108 
 
  

   
 
12G.616 Protocol v4.2 (04Jan2016)  109 
Appendix VI. Blood/Tissue Specimen Collection and Banking  
  
Blood  
1. Blood specimen collections will be performed on each patient.  
2. Timing: baseline at radiation simulation visit, conclusion of diet and 4 weeks after 
radiation.  
3. Collection: Each time, 20-30 cc blood will be collected using two sodium heparin 
vacutainer tubes.  
4. Sample preparation: Blood specimens collected from Thomas Jefferson 
University should be processed locally the same day of collection. Processed 
samples (serum and plasma) should be given to [CONTACT_853768] or member of her 
laboratory.  
5. Process: All blood specimens collected will be processed locally within 24 hr of 
collection. The blood specimens will be processed for plasma and serum.  
6. Storage: Plasma specimens and serum will be stored in liquid nitrogen or a  -70-
80ï‚°C freezer  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  110 
Appendix VII. Case Report F orms 
 
THOMAS JEFFERSON UNIVERSITY HOSPI[INVESTIGATOR_853735]: A Feasibility Pi[INVESTIGATOR_853736]â€™s Initials         Case#              Dose Level        
 
 
MR#                          Date of birth     
 
 
Address__________________________________________________________________ 
 
_________________________________________________________________________ 
 
 
Telephone_________________________________  
 
 
Sex    Race_______________ Ethnicity ___________________ 
 
Insurance________________________________ 
 
 
Radiation Oncologist:       
 
Medical Oncologist:       
 
Resident:        
 
 
 
 
 
 
Signature_________________________________________ Date______________  
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  111 
CAREFOR Study Case Report Form (CRF)â€”Screening Visit 
Date of Screening:      
 
Patient Demographics 
Age:   Race:          
Current Address (for mailing purposes):  
             
             
 
Emergency Contact:           
  
[CONTACT_156289]:          
Highest Education Level Completed:      
 
 
Past Medical History and Relevant Clinical Information 
Date of Diagnosis:            
How was the mass found?  
ïƒ¿ MMG  
ïƒ¿ SBE 
ïƒ¿ Physician Exam 
ïƒ¿ Other:     
 
Date of most recent mammogram:    
Side of Breast Mass (L v. R):    
Previous History of Breast Cancer:         
             
Family History of Breast Cancer:         
             
If applicable, what treatment was received for previous breast cancer:     
           Previous History of any 
other malignancy (include dates of diagnosis and NED date):      
             
       
 
Is this patient a candidate for breast conservation?       
            Oral 
Contraceptive Use (current or past):  Y  or  N 
Hormone Replacement Use:  Y  or  N 
Date of last period    Age at menarche:     
 
Gravida/Para:        
 
Previous diagnosis of any of the following: 
 Unstable Angina 
 Coronary Artery Disease 
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188389], if yes please indicate date of event:     
 CHF 
 Valvular Disease 
 Arrythmias/Pacemaker Placement 
 Diabetes 
 Severe Asthma 
 Autoimmune Disorder (specifically SLE, scleroderma, dermatomyositis) 
 Any Disease Requiring Chronic Steroid Use 
Inflammatory Bowel Disease 
Celiac Disease 
Chronic Pancreatitis 
Chronic Diarrhea or Vomiting 
Active Eating Disorder 
Renal Failure or CKD 
Pi[INVESTIGATOR_853737] (within the last 6 months, include diagnosis and length of stay):   
             
          
 
Recent Weight Loss (include baseline weight and pounds lost):      
           
 
Surgical History 
Please indicate any major surgeries, the date or at least the year of the surgery and whether or not 
there were any post-op complications: 
Surgery Date  Pre-op Diagnosis  Post-Op Complications 
             
            
             
             
            
 
 
Pertinent Social History 
Current Occupation:           
Habitation Status (alone or with family):        
Alcohol Use:            
Previous of Current Use of Illicit Drugs:        
Smoker (indicate pack/year for current or past and year of cessation):     
             
          
 
Currently Sexually Active:  Y  or  N 
   
 
12G.616 Protocol v4.2 (04Jan2016)  113 
If yes, what type of contraception is being used?      
If no contraception, is the patient willing to use contraception for the duration of the study/treatment 
period?          
 
Allergies: 
             
             
             
 
Current Medications (indicate dose, route, frequency and start date):  
Medication  Dose  Route  Frequency  Start Date 
             
             
             
             
             
             
             
             
             
 
 
 
 
 
 
 
 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  114 
Physical Examination 
Height:    Weight:   BMI:     
 
Karnofsky Performance Status: 
Please assess the patientâ€™s  performance status based on the table provided. Circle the most appropriate 
functional capacity. 
Able to carry on normal activity and to work; no 
special care needed.    100   Normal no complaints; no evidence of 
disease.  
90 Able to carry on normal activ ity; minor 
signs or symptoms of disease.  
80 Normal activity with effort; some signs 
or symptoms of disease.  
Unable to work; able to live at home and care for 
most personal needs; varying amount of 
assistance needed.  70 Cares for self; unable to carry on  
normal activity or to do active work.  
[ADDRESS_1188390] of his personal 
needs.  
50 Requires considerable assistance and 
frequent medical care.  
Unable to care for self; requires equivalent of 
institutional or hospi[INVESTIGATOR_10422]; disease may be 
progressing rapi[INVESTIGATOR_375].  40 Disabled; requires special care and 
assistance.  
30 Severely disabled; hospi[INVESTIGATOR_62420].  
20 Very sick; hospi[INVESTIGATOR_62421]; active supportive tr eatment 
necessary.  
10 Moribund; fatal processes progressing 
rapi[INVESTIGATOR_375].  
0 Dead  
 
 
 
 
   
 
12G.616 Protocol v4.2 (04Jan2016)  115 
 
  

   
 
12G.616 Protocol v4.2 (04Jan2016)  116 
Thomas Jefferson University 
Kimmel Cancer Center 
 
CAREFOR Inclusion/Exclusion Criteria Checklist 
 
Inclusion Criteria: 
Patients must meet all of the following criteria in order to be considered for entry into the 
CAREFOR trial. 
ïƒ¿ Pathologically confirmed diagnosis of DCIS or invasive breast cancer 
ïƒ¿ Female patient, 18 years or older 
ïƒ¿ Candidate for breast conservation 
ïƒ¿ Karnofsky performance status at least 80%  
ïƒ¿ Negative serum beta-hCG if appropriate 
ïƒ¿ Willing to use contraception, not sexually active or post-menopausal 
ïƒ¿ BMI > 21 
ïƒ¿ Weight 
> 100lbs 
 
Exclusion Criteria: 
In addition to meeting inclusion criteria, patients are ineligible for enrollment if any of the 
following exclusion criteria are met. 
ïƒ¿ Intentional weight loss > 10% of total body weight within the last 3 months prior to 
trial enrollment. 
ïƒ¿ Prior non-breast invasive malignancy, unless free of disease for at least 1 year prior to 
trial enrollment. 
ïƒ¿ Two or more breast cancers not resectable through a single lumpectomy site. 
ïƒ¿ Non-epi[INVESTIGATOR_335126]. 
ïƒ¿ Prior radiotherapy to ipsilateral breast that would result in overlappi[INVESTIGATOR_853738]. 
ïƒ¿ Severe, active comorbidities to include any one of the following:  
ï‚§ Unstable angina or CHF requiring hospi[INVESTIGATOR_6924] 6 months 
ï‚§ COPD exacerbation requiring hospi[INVESTIGATOR_21342] 30 days of registration 
ï‚§ Transmural myocardial infarct in the past 6 months 
ï‚§ Acute bacterial or fungal infection requiring IV antibiotics at the time of 
registration 
   
 
12G.616 Protocol v4.2 (04Jan2016)  117 
ï‚§ Hepatic insufficiency resulting in clinical jaundice 
ï‚§ AIDS or HIV positive according to CDC guidelines   
ïƒ¿ Active systemic lupus erythematosus, scleroderma or dermatomyositis with rash. 
ïƒ¿ Medical or psychiatric condition preventing the patient from providing informed consent or 
from adhering to diet guidelines. 
ïƒ¿ Currently taking diet supplements 
ïƒ¿ Active gastrointestinal/malabsorption syndrome to include: 
ï‚§ Inflammatory Bowel Disease 
ï‚§ Celiac Disease 
ï‚§ Chronic Pancreatitis 
ï‚§ Chronic Diarrhea or Vomiting 
ï‚§ Active Eating Disorder 
ïƒ¿ Currently using steroids 
ïƒ¿   
ïƒ¿ Active/history of substance abuse or dependency to include prescription or illicit drugs 
as well as alcohol. 
ïƒ¿ Decisionally impaired patients. 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188391] for Screening Visit: 
 
Infor med Consent for Trial Obtained   
All Sections of CRF Completed   
Inclusion/Exclusion Criteria Evaluated   
Blood draw: Beta -HCG   
H&P; Performance Status   
Weight, BMI   
Based on screening patient appears eligible   
 
 
 
 
 
 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  119 
CAREFOR Study Case Report Form (CRF)â€”Radiation Treatment Planning Visit 
Date of Sim Visit:      
 
Lumpectomy Details 
Please indicate the actual date of the lumpectomy, whether or not there were any post-op 
complications and the status of the Path report: 
Surgery Date  Pre-op Diagnosis  Post-Op Complications 
             
            
 
Path Report Received?   Y  or  N 
Attach a copy of the Path Report to this visit. 
 
Verify Allergies: 
             
             
             
 
Changes to Current Medications (indicate dose, route, frequency and start date ): 
Medication  Dose  Route  Frequency  Start Date 
             
             
             
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  120 
Physical Examination 
Height:    Weight:   BMI:     
Vital Signs: BP:      HR:   Temp:   RR:   
Caliper Measurements:          
 
Bioimpedance Measurement:         
 
Please indicate the status (normal or abnormal) of each system listed below. If abnormal, please make 
notes. Give detailed description of breast exam in the notes section. 
Organ System   Status    Notes 
CVS   Normal Abnormal        
             
Pulm   Normal Abnormal       
             
 
GI   Normal Abnormal       
             
 
Neuro   Normal Abnormal       
             
 
Breast   Normal Abnormal       
             
             
 
 
CTCAE v4.[ADDRESS_1188392]-radiation. 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  121 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  122 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  123 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188393] for Sim Visit: 
 
Pathology Report Obtained and Attached   
Baseline  Labs: CBC w/diff, CMP, HbA1c  
Serum: IGF -1, adiponectin, leptin, estradiol, triglyce rides, 
ESR, insulin, glucose   
Blood Sample sent to [CONTACT_853768]â€™s lab for further analysis   
All Sections of CRF Completed   
FACT -B Completed by [CONTACT_853765], BMI , Body fat persent, bioimpedance   
Food diaries collected at this visit   
Dietary Counselin g for caloric restriction  diet alterations   
 
Please attach a copy of patientâ€™ s labs when available. 
Please attach a copy of food diary. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  126 
CAREFOR Study Case Report Form (CRF)â€”Diet Support Visit: Day 7 of CR Diet 
Date of Visit:      
 
Changes to Current Medications (indicate dose, route, frequency and start date ): 
Medication  Dose  Route  Frequency  Start Date 
             
             
             
             
 
Height:    Weight:   BMI:     
Vital Signs: BP:      HR:   Temp:   RR:   
 
Food Diary Received and Completed:  Y  or  N 
If no, must collect at next visit. 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188394] for D7 Visit: 
 
All Sections of CRF Completed   
Weight, BMI   
Food diary collected at this visit   
 
Please attach a copy of food diary. 
24 hour recall of food inta ke: 
 
Meal     Food Type     Amount 
 
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  128 
CAREFOR Study Case Report Form (CRF)â€”Diet Support Visit: Day 14 of CR Diet 
Date of Visit:      
 
Changes to Current Medications (indicate dose, route, frequency and start date ): 
Medication  Dose  Route  Frequency  Start Date 
             
             
             
             
 
Height:    Weight:   BMI:     
Vital Signs: BP:      HR:   Temp:   RR:   
 
Food Diary Received and Completed:  Y  or  N 
If no, must collect at next visit. 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188395] for D14 Visit: 
 
All Sections of CRF Completed   
Weight, BMI   
Food diary col lected at this visit   
 
Please attach a copy of food diary. 
24 hour recall of food intake: 
 
Meal     Food Type     Amount 
 
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  130 
CAREFOR Study Case Report Form (CRF)â€”Radiation Treatment 
Date of Visit:      Weeks of Radiation Completed:    
 
Changes to Current Medications (indicate dose, route, frequency and start date ): 
Medication  Dose  Route  Frequency  Start Date 
             
             
             
             
 
Food Diary Received and Completed:  Y  or  N          If no, must collect at next visit. 
 
Physical Examination 
Height:    Weight:   BMI:     
Vital Signs: BP:      HR:   Temp:   RR:   
 
Please indicate the status (normal or abnormal) of each system listed below. If abnormal, please make 
notes. Give detailed description of breast exam in the notes section. 
 
Breast   Normal Abnormal       
             
             
Erythema  Mild  Moderate       Severe 
Hyperpi[INVESTIGATOR_853739]  
 
 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188396] for Visit: 
  
All Sections  of CRF Completed   

   
 
12G.616 Protocol v4.2 (04Jan2016)  132 
Weight, BMI   
Food diary collected at this visit   
Dietary Counseling  for caloric restriction  diet alterations   
 
Please attach a copy of patientâ€™ s labs when available. 
Please attach a copy of food diary. 
 
24 hour recall of food intake: 
 
Meal     Food Type     Amount 
 
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  133 
CAREFOR Study Case Report Form (CRF)â€”Post RT Visit 1 
Date of Visit:      Date Radiation Completed:    
 
Height:    Weight:   BMI:     
Vital Signs: BP:      HR:   Temp:   RR:   
 
Changes to Current Medications (indicate dose, route, frequency and start date ): 
Medication  Dose  Route  Frequency  Start Date 
             
             
             
             
 
Food Diary Received and Completed:  Y  or  N               If no, must collect at next visit. 
 
Breast Exam  Normal  Abnormal  Notes:     
                                                                                                                
            
Erythema  Mild  Moderate       Severe 
Hyperpi[INVESTIGATOR_853740] v4.0 Evaluation 
 
 
 
 
 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188397] for Visit: 
  
All Sections of CRF Completed   
Weight, BMI   
Food diary collected at this visit   
 
Please attach a copy of patientâ€™ s labs when available. 
Please attach a copy of food diary. 
 
24 hour recall of food intake: 
 
Meal     Food Type     Amount 
 
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
 
 
 
 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  135 
CAREFOR Study Case Report Form (CRF)â€”Post RT Visit 2 
Date of Visit:      Date Radiation Completed:    
 
Height:    Weight:   BMI:     
Vital Signs: BP:      HR:   Temp:   RR:   
Caliper Measurements:          
 
Bioimpedance Measurement:         
 
Changes to Current Medications (indicate dose, route, frequency and start date ): 
Medication  Dose  Route  Frequency  Start Date 
             
             
             
             
 
Food Diary Received and Completed:  Y  or  N 
If no, must collect at next visit. 
 
Breast Exam  Normal  Abnormal  Notes:     
                                                                                                                
            
Erythema  Mild  Moderate       Severe 
Hyperpi[INVESTIGATOR_853741] v4.0 Evaluation 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  136 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  137 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  138 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  139 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188398] for Visit: 
Completion  Labs: CBC w/diff, CMP, HbA1c  
Serum: IGF -1, adiponectin, leptin, estradiol, triglycerides, 
ESR, insulin, glucose   
Blood Sample sent to Dr . Simoneâ€™s lab for further analysis   
All Sections of CRF Completed   
FACT -B Completed by [CONTACT_853765], BMI , Body fat percent, bioimpedance   
Food diary collected at this visit   
 
Please attach a copy of patientâ€™ s labs when available. 
Please attach a copy of food diary. 
 
24 hour recall of food intake: 
 
Meal     Food Type     Amount 
 
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
 
 
 
 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  141 
CAREFOR Study Case Report Form (CRF)â€”Follow-up Visit 
Date of Visit:      
 
Physical Examination 
Height:    Weight:   BMI:     
Vital Signs: BP:      HR:   Temp:   RR:   
Caliper Measurements:          
 
Bioimpedance Measurement:         
 
Changes to Current Medications (indicate dose, route, frequency and start date ): 
Medication  Dose  Route  Frequency  Start Date 
             
             
             
             
 
Please indicate the status (normal or abnormal) of each system listed below. If abnormal, please make 
notes. Give detailed description of breast exam in the notes section. 
Breast Exam  Normal  Abnormal  Notes:     
                                                                                                                
            
Erythema  Mild  Moderate       Severe 
Hyperpi[INVESTIGATOR_853742] v4.0 Evaluation 
 
 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  142 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  143 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  144 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188399] for Follow-up Visit: 
 
Follow -up Labs: CBC w/diff, CMP, HbA1c  
Serum: IGF -1, adiponectin, leptin, estradiol, triglycerides, 
ESR, insulin, glucose   
Blood Sample sent to [CONTACT_853768]â€™s lab for further analysis   
All Sections of CRF Completed   
FACT -B Completed by [CONTACT_853765], BMI , Body fat percent, bioimpedance   
Food diaries collected at this visit   
 
Please attach a copy of patientâ€™ s labs when available. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  147 
THOMAS JEFFERSON UNIVERSITY HOSPI[INVESTIGATOR_853735]: A Feasibility Pi[INVESTIGATOR_853743] ________       MR# _______________ 
 
     Patient ID # _________ 
 
 
Please initial below: 
 
 
_____ I no longer wish to participate in this research study. 
 
 
_____ I am withdrawing from the study treatment, but I agree to the research coordinator 
following up with me periodically to see how I am doing. 
 
 
 
Please sign below: 
 
 
Patient: ____________________ ________________  Date: ___________  
 
 
Witnessed By: _______________________________ Date: ___________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
12G.616 Protocol v4.2 (04Jan2016)  148 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

   
 
12G.616 Protocol v4.2 (04Jan2016)  150 
Thomas Jefferson University Hospi[INVESTIGATOR_853744]: 
 
 
 
 
 
Physician Signature: ___________________________________   Date:____________ 
 
 
 
 
 
Study :                                       Patient Case No.                         Time Frame/Cycle #    
                                                                               Intermittent RT 
(circle one): Y or N, N/A 
   
 
12G.616 Protocol v4.2 (04Jan2016)  151 
 
  

   
 
12G.616 Protocol v4.2 (04Jan2016)  152 
Appendix VIII. Recruitment Flyer 
 
 
 
 
 
Appendix IX. Food Diaries 
 
Printed Food Diary: 
 
 
 
Online Food Diary: 
Accessible at: http://www. myfitnesspal.com  
 
 
 
 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  153 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  154 
Appendix X. 
Thomas Jefferson University 
Kimmel Cancer Center 
 
CAREFOR Inclusion/Exclusion Criteria Checklist 
 
Inclusion Criteria: 
Patients must meet all of the following criteria in order to be considered for entry into the 
CAREFOR trial. 
ïƒ¿  Pathologically proven diagnosis of DCIS or invasive breast cancer  
ïƒ¿  Ability to have breast conservation as determined by [CONTACT_853766] 
ïƒ¿  The patient must be female 
ïƒ¿  Age â‰¥ 18 
ïƒ¿ If multifocal breast cancer, then it must be able to be resected through a single 
lumpectomy incision  
ïƒ¿  Appropriate stage for protocol entry, including no clinical evidence for distant 
metastases, based upon the following minimum diagnostic workup: 
ïƒ¿  History/physical examination, including breast exam and documentation of 
weight and Karnofsky Performance Status of 80-100% at study entry.  
ïƒ¿  Women of childbearing potential must have a negative serum pregnancy test 
within 14 days of study entry 
ïƒ¿  Women of childbearing potential must be non-pregnant and non-lactating and 
willing to use medically acceptable form of contraception during radiation therapy 
ïƒ¿  Patient must capable of and provide study specific informed consent prior to 
study entry 
ïƒ¿  BMI â‰¥21  
ïƒ¿  Weight â‰¥100lbs   
ïƒ¿  No prior history of non-breast invasive malignancies in the past 1year  
ïƒ¿  Patient must not have any of the following severe, active co-morbidity, defined as 
follows: 
o Unstable angina and/or congestive heart failure requiring hospi[INVESTIGATOR_138474] [ADDRESS_1188400] 6 months 
o Acute bacterial or fungal infection requiring intravenous antibiotics at the 
time of registration; 
o Chronic Obstructive Pulmonary Disease exacerbation or other respi[INVESTIGATOR_853745] 30 days 
before registration; 
   
 
12G.616 Protocol v4.2 (04Jan2016)  155 
o Hepatic insufficiency resulting in clinical jaundice and/or coagulation 
defects; note, however,that laboratory tests for liver function and 
coagulation parameters are not required for entry into this protocol 
o Acquired Immune Deficiency Syndrome (AIDS) or HIV positive based upon 
current CDC definition; note,however, that HIV testing is not required for 
entry into this protocol. The need to exclude patients with AIDS or HIV 
from this protocol is necessary because anti-retrivirals may alter patient 
metabolism. 
ïƒ¿ Patient must not have active systemic lupus, erythematosus, or any history of 
scleroderma, dermatomyositis with active rash 
ïƒ¿ No prior radiotherapy to the ipsilateral breast or prior radiation to the region of the 
breast that would result in overlap of radiation therapy fields 
ïƒ¿ Patient may not have any active Gastrointestinal/Malabsorption disorder at the 
discretion of the Principal Investigator 
o Inflammatory Bowel Disease 
o Celiac Disease 
o Chronic Pancreatitis 
o Chronic Diarrhea or Vomiting 
o Active Eating Disorder 
ïƒ¿  
ïƒ¿ Not currently taking steroids 
ïƒ¿ No history of or current active drug/alcohol dependence .   
ïƒ¿ No patients with decisional impairment. 
 
Exclusion Criteria 
ïƒ¿  Patient is not a candidate for breast conservation. 
ïƒ¿  Patient is male. 
ïƒ¿  Age <18 years 
ïƒ¿ Patient has evidence of distant metastases 
ïƒ¿ Karnofsky Performance Status less than 80% within 60 days prior to 
study. 
ïƒ¿ Ipsilateral mammogram done greater than 6 months prior to study. 
ïƒ¿ Women of childbearing potential with a positive serum beta hCG. 
ïƒ¿ Patient has a history of dementia, psychosis or other disorder 
affecting their mental status to the point where they cannot consent 
or comply with study guidelines. 
ïƒ¿ BMI < 21 
ïƒ¿ Weight < 100lbs 
ïƒ¿ Unintentional weight loss â‰¥10% in the last 3 mos 
ïƒ¿ Prior invasive non-breast malignancy (except non-melanomatous 
skin cancer, carcinoma in situ of the cervix) unless disease free for 
a minimum of 2 years prior to registration 
   
 
12G.616 Protocol v4.2 (04Jan2016)  156 
ïƒ¿ Two or more breast cancers not resectable through a single 
lumpectomy incision 
ïƒ¿ Non-epi[INVESTIGATOR_335126] 
ïƒ¿ Prior radiotherapy to the ipsilateral breast or prior radiation to the 
region of the breast that would result in overlap of radiation therapy 
fields 
ïƒ¿ Severe, active co-morbidity, defined as follows: 
o Unstable angina and/or congestive heart failure requiring 
hospi[INVESTIGATOR_854] [ADDRESS_1188401] 6 months 
o Acute bacterial or fungal infection requiring intravenous 
antibiotics at the time of registration; 
o Chronic Obstructive Pulmonary Disease exacerbation or 
other respi[INVESTIGATOR_853746] 30 days before registration; 
o Hepatic insufficiency resulting in clinical jaundice and/or 
coagulation defects; note, however,that laboratory tests for 
liver function and coagulation parameters are not required for 
entry into this protocol 
o Acquired Immune Deficiency Syndrome (AIDS) or HIV 
positive based upon current CDC definition; note,however, 
that HIV testing is not required for entry into this protocol. 
The need to exclude patients with AIDS or HIV from this 
protocol is necessary because anti-retrivirals may alter 
patient metabolism. 
ïƒ¿ Active systemic lupus erythematosus, or any history of scleroderma, 
dermatomyositis with active rash 
Active Gastrointestinal/Malabsorption disorder at the discretion of 
the Principal Investigator 
o  Inflammatory Bowel Disease 
o Celiac Disease 
o  Chronic Pancreatitis 
o Chronic Diarrhea or Vomiting 
o Active Eating Disorder 
ïƒ¿ Current use of steroids 
ïƒ¿ Active drug/alcohol dependence or abuse history.   
ïƒ¿ Decisionally impaired patients. 
 
 
 
 
 
 
 
 
   
 
12G.616 Protocol v4.2 (04Jan2016)  157 
 
 
 
  
   
 
12G.616 Protocol v4.2 (04Jan2016)  [ADDRESS_1188402]-B 
Assessment 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  159 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  160 
 

   
 
12G.616 Protocol v4.2 (04Jan2016)  161 
 
